<SEC-DOCUMENT>0001178913-23-002276.txt : 20230623
<SEC-HEADER>0001178913-23-002276.hdr.sgml : 20230623
<ACCEPTANCE-DATETIME>20230623161645
ACCESSION NUMBER:		0001178913-23-002276
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		8
CONFORMED PERIOD OF REPORT:	20230623
FILED AS OF DATE:		20230623
DATE AS OF CHANGE:		20230623

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BioLineRx Ltd.
		CENTRAL INDEX KEY:			0001498403
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35223
		FILM NUMBER:		231037889

	BUSINESS ADDRESS:	
		STREET 1:		2 HAMA-AYAN STREET
		STREET 2:		MODI-IN TECHNOLOGY PARK
		CITY:			MODI-IN
		STATE:			L3
		ZIP:			7177871
		BUSINESS PHONE:		972-2-548-9100

	MAIL ADDRESS:	
		STREET 1:		2 HAMA-AYAN STREET
		STREET 2:		MODI-IN TECHNOLOGY PARK
		CITY:			MODI-IN
		STATE:			L3
		ZIP:			7177871

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BioLineRX, Ltd.
		DATE OF NAME CHANGE:	20100805
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk2329906.htm
<DESCRIPTION>6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using Broadridge PROfile 23.5.1.5152
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div class="BRPFPageHeader">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="line-height: 1.25; font-size: 14pt;">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">WASHINGTON, D.C. 20549</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="line-height: 1.25; font-size: 14pt;">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-weight: bold;">FORM 6-K</div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER</div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">PURSUANT TO RULE 13a-16 OR 15d-16 OF</div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">THE SECURITIES EXCHANGE ACT OF 1934</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-style: italic; font-weight: bold;">For the month of June 2023</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Commission file number: 001-35223</div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">_______________________</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="line-height: 1.25; font-size: 16pt;">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-weight: bold;">BioLineRx Ltd.</div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">(Translation of registrant&#8217;s name into English)</div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">_______________________</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">2 HaMa&#8217;ayan Street<br>
        Modi&#8217;in 7177871, Israel</div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;(Address of Principal Executive Offices)</div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">_______________________</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: &#160; &#160; &#160; &#160;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Form 20-F <font style="font-family: 'Segoe UI Symbol',sans-serif;">&#9746;</font> &#160; &#160; &#160; &#160; Form 40-F&#160;<font style="font-family: 'Segoe UI Symbol',sans-serif;">&#9744;</font></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">The Registrant announces that it will hold an Annual Meeting of Shareholders on August 7, 2023, at 3:00 p.m. (Israel time) at the Registrant&#8217;s office,
        Modi&#8217;in Technology Park, 2 HaMa&#8217;ayan Street, Modi&#8217;in 7177871, Israel. Attached hereto as&#160;<a href="exhibit_1.htm">Exhibit 1</a>,&#160;<a href="exhibit_2.htm">Exhibit 2</a>&#160;and&#160;<a href="exhibit_3.htm">Exhibit 3</a>, are,
        respectively, the Notice of Annual General Meeting and Proxy Statement, Proxy Card and Voting Instruction Card for holders of American Depositary Shares.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">This Form 6-K, including all exhibits hereto, is hereby incorporated by reference into all effective registration statements filed by the registrant
        under the Securities Act of 1933.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
        undersigned, thereunto duly authorized.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z3c2192edaac34b2eae0449dfd26255e9" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 49.22%; vertical-align: top;">
              <div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">&#160;</div>
            </td>
            <td style="width: 28.14%; vertical-align: top;" colspan="2">
              <div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-weight: bold;">BioLineRx Ltd.</div>
              <div style="line-height: 1.25; color: #000000; font-size: 12pt; font-weight: bold;"> <font style="font-size: 10pt;"><br>
                </font></div>
            </td>
            <td style="width: 22.65%; vertical-align: top;">
              <div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.22%; vertical-align: top;">
              <div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">&#160;</div>
            </td>
            <td style="width: 3.85%; vertical-align: top;">
              <div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">By:</div>
            </td>
            <td style="width: 24.28%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">/s/ Philip A. Serlin</div>
            </td>
            <td style="width: 22.65%; vertical-align: top;">
              <div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.22%; vertical-align: top;">
              <div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">&#160;</div>
            </td>
            <td style="width: 3.85%; vertical-align: top;">
              <div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">&#160;</div>
            </td>
            <td style="width: 24.28%; vertical-align: top;">
              <div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">Philip A. Serlin</div>
            </td>
            <td style="width: 22.65%; vertical-align: top;">
              <div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.22%; vertical-align: top;">
              <div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">&#160;</div>
            </td>
            <td style="width: 3.85%; vertical-align: top;">
              <div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">&#160;</div>
            </td>
            <td style="width: 24.28%; vertical-align: top;">
              <div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">Chief Executive Officer</div>
            </td>
            <td style="width: 22.65%; vertical-align: top;">
              <div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">&#160;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Dated: June 23, 2023</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25; font-size: 12pt;">
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>exhibit_1.htm
<DESCRIPTION>NOTICE AND PROXY STATEMENT
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using Broadridge PROfile 23.5.1.5152
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div style="text-align: right;"> <u><font style="font-weight: bold;">Exhibit 1</font></u><br>
    </div>
    <div> <br>
    </div>
    <div>
      <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">BIOLINERX LTD.</div>
      <div style="text-align: justify; line-height: 1.25; color: #000000;">&#160;</div>
      <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">To be held on August 7, 2023</div>
      <div style="text-align: justify; line-height: 1.25; color: #000000;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="color: #000000;">Notice is hereby given that the Annual General Meeting of the shareholders (the &#8220;</font><font style="font-weight: bold; color: #000000;">Meeting</font><font style="color: #000000;">&#8221;) of BioLineRx Ltd. (the &#8220;</font><font style="font-weight: bold; color: #000000;">Company</font><font style="color: #000000;">&#8221;) will be held at the offices of the Company at Modi&#8217;in Technology Park, 2 HaMa&#8217;ayan Street,
          Modi&#8217;in 7177871, Israel, on August 7, 2023, at 3</font>:00 p.m. (Israel time), for the <font style="color: #000000;">following purposes:</font></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze4d0838ef30242a9bb98af410de1c140">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">1.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #000000;">To re-elect the </font>following persons to the Board of Directors, each to serve until the next annual general meeting of shareholders and until their respective successors are duly elected and qualified:
                Aharon Schwartz, Michael Anghel, B.J. Bormann, Raphael Hofstein and Sandra Panem, or each to serve for staggered terms ending at the 2024, 2025 and 2026 annual general meetings of shareholders, if Proposal 3 is approved.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z005520ccc0284c4ea03efffdf133435a">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">2.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>To approve the grant of equity compensation to Philip Serlin, the Company&#8217;s Chief Executive Officer.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf69ac834339345d181d07d2ab2a686ee">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">3.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>To approve certain amendments to the Company&#8217;s Articles of Association relating to the appointment of directors of the Company, including to classify the Board of Directors (other than the external directors) into three classes with
                staggered three-year terms.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z03f31cdfc4de4220880c680c0e861bfc">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">4.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>To approve the reappointment of Kesselman &amp; Kesselman, Certified Public Accountants (Isr.), a member firm of PricewaterhouseCoopers International Limited, as the Company&#8217;s independent registered public accounting firm for the year
                ending December 31, 2023, and to authorize the Audit Committee of the Board of Directors to fix the compensation of said auditors in accordance with the scope and nature of their services.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In addition, at the Meeting, representatives of the Company&#8217;s management will be available to review and discuss the Company&#8217;s <font style="color: #000000;">financial</font>
        statements for the year ended December 31, 2022, and to transact such other business<font style="color: #000000;"> as may properly come before the Meeting.</font></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="color: #000000;">Shareholders of record </font>and holders of the Company&#8217;s American Depositary Shares (&#8220;<font style="font-weight: bold;">ADSs</font>&#8221;) of record <font style="color: #000000;">at the close of business in New York on June 30, 2023 (the &#8220;</font><font style="font-weight: bold; color: #000000;">Record Date</font><font style="color: #000000;">&#8221;) are entitled to notice of and to vote at the Meeting</font>
        and any adjournments or postponements thereof<font style="color: #000000;">. All shareholders are cordially invited to attend the Meeting in person.</font></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="color: #000000;">Whether or not you plan to attend the Meeting, </font>it is important that your ordinary shares be represented.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">A holder of ordinary shares at the close of business on the Record Date shall also be entitled to participate in the Meeting by proxy, which proxy shall be in writing and signed
        by the appointing party or its authorized attorney, and if the appointing party is a corporation, the appointment shall be in writing signed by authorized corporate signatories together with the company stamp or by an authorized attorney. &#160;<font style="color: #000000;">A proxy from the holder of ordinary shares must be received by the Company no later than 3:00 p.m., Israel time (8:00 a.m. ET), on August 5, 2023 to be validly included in the tally of ordinary shares voted at the Meeting.
          Return of your </font><font style="color: #252525;">proxy</font><font style="color: #000000;"> does not deprive you of your right to attend the Meeting, to revoke the </font><font style="color: #252525;">proxy</font><font style="color: #000000;"> or to vote your shares in person.</font></div>
      <div style="text-align: justify; line-height: 1.25; color: #000000;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Holders of ADSs (whether registered in their name or in &#8220;street name&#8221;) will receive voting instruction forms from the Bank of New York Mellon (which acts as the Depositary for
        the ADSs) in order to instruct their banks, brokers or other nominees on how to vote, and they are kindly requested to complete, date, sign and mail the voting instruction form in the envelope provided at the earliest convenience so that it will be
        received no later than the date and time indicated on the voting instruction form.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="color: #000000;">Beneficial owners who hold their shares through members of the Tel Aviv Stock Exchange (&#8220;</font><font style="font-weight: bold; color: #000000;">TASE</font><font style="color: #000000;">&#8221;) may (i) vote their shares in person at the Meeting by presenting a certificate signed by a member of the TASE which complies with the Israel Companies Regulations (Proof of Ownership for Voting in General Meetings),
          5760-2000 as proof of ownership of the shares, (ii) send such a certificate along with a duly executed </font><font style="color: #252525;">proxy</font><font style="color: #000000;"> to the Company at 2 HaMa&#8217;ayan Street, Modi&#8217;in 7177871, Israel,
          Attention: Chief Financial Officer, to be received by the Company no later than 3:00 p.m., Israel time (8:00 a.m. ET), on August 5, 2023; or (iii) complete the Internet voting process via the electronic voting system of the Israel Securities
          Authority (the &#8220;</font><font style="font-weight: bold; color: #000000;">ISA</font><font style="color: #000000;">&#8221;) after receiving a personal identifying number, an access code and additional information regarding this Meeting from the member of
          the TASE and after carrying out a secured identification process, up to six hours before the time set for the Meeting.</font></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <!--PROfilePageNumberReset%LCR%2%- % -%-->
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The full version of the proposed resolutions may be viewed in the proxy statement, which together with the accompanying voting instruction form and proxy card (collectively, the
        &#8220;<font style="font-weight: bold;">Proxy Materials</font>&#8221;), will be available to the public on the U.S. Securities and Exchange Commission&#8217;s website at http://www.sec.gov. This Notice of Annual General Meeting of Shareholders and the Proxy
        Materials will also be submitted to the ISA and TASE and will be available on their respective websites for listed company reports. The Proxy Materials will also be made available on our corporate website and may also be viewed at our offices
        during regular business hours at <font style="color: #000000;">2 HaMa&#8217;ayan Street, Modi&#8217;in 7177871</font>.&#160; Detailed voting instructions are provided in the proxy statement, the voting instruction form and the proxy card.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">
        <table cellspacing="0" cellpadding="0" border="0" id="zb34ed2343abf4cafae592718b7ce3d6f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

            <tr>
              <td style="width: 50.00%;">
                <div>&#160;</div>
              </td>
              <td style="width: 50.00%;">
                <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">By Order of the Board of Directors,</div>
                <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                </div>
                <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">Dr. Aharon Schwartz<br>
                  Chairman of the Board of Directors</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; color: #000000;">June 23, 2023</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">- ii -</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;"><font style="color: #252525;">PROXY</font><font style="color: #000000;"> STATEMENT</font></div>
      <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">_________</div>
      <div style="text-align: justify; line-height: 1.25; color: #000000;">&#160;</div>
      <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">BIOLINERX LTD.</div>
      <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">Modi&#8217;in Technology Park</div>
      <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">2 HaMa&#8217;ayan Street</div>
      <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">Modi&#8217;in 7177871</div>
      <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">Israel</div>
      <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">________</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">ANNUAL GENERAL MEETING OF SHAREHOLDERS</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">To be held on August 7, 2023</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">This Proxy <font style="color: #000000;">Statement</font> is being furnished to the holders of ordinary shares, par value NIS <font style="color: #000000;">0.10 </font>per
        share (the &#8220;<font style="font-weight: bold;">Ordinary Shares</font>&#8221;), and to holders of American Depositary Shares (&#8220;<font style="font-weight: bold;">ADSs</font>&#8221;), each representing 15 Ordinary Shares issued by the Bank of New York Mellon (&#8220;<font style="font-weight: bold;">BNY Mellon</font>&#8221;), in connection with the solicitation of proxies on behalf of the Board of Directors of <font style="color: #000000;">BioLineRx </font>Ltd. (&#8220;<font style="font-weight: bold;">we</font>,&#8221; &#8220;<font style="font-weight: bold;">us</font>,&#8221; &#8220;<font style="font-weight: bold;">our</font>,&#8221; or the &#8220;<font style="font-weight: bold;">Company</font>&#8221;) to be voted at the<font style="color: #000000;"> Annual General Meeting of Shareholders (the &#8220;</font><font style="font-weight: bold; color: #000000;">Meeting</font><font style="color: #000000;">&#8221;) to be held on August 7, 2023, at </font>3:00 p.m., Israel time,<font style="color: #000000;"> or at any adjournment thereof, at the offices of the Company
          at Modi&#8217;in Technology Park, 2 HaMa&#8217;ayan Street, Modi&#8217;in 7177871, Israel.</font></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">INFORMATION CONCERNING SOLICITATION AND VOTING</div>
      <div style="text-align: justify; line-height: 1.25; color: #000000;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; color: #000000; font-weight: bold;">Record Date and Shares Outstanding</div>
      <div style="text-align: justify; line-height: 1.25; color: #000000;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: #000000;">The record date for determining which of our shareholders is entitled to notice of, and to vote at, the Meeting is established as of the close of trade on June
        30, 2023 (the &#8220;<font style="font-weight: bold;">Record Date</font>&#8221;).&#160; As of the date hereof, we have outstanding and entitled to vote 922,958,942 of our Ordinary Shares.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="color: #000000;">You are entitled to vote at the Meeting if you were a shareholder </font>or holder of our ADSs of record<font style="color: #000000;"> at the close
          of business in New York on the Record Date.</font></div>
      <div style="text-align: justify; line-height: 1.25; color: #000000;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Board Recommendation</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">The Board of Directors recommends that you vote &#8220;FOR&#8221; each of the proposals on the agenda.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; color: #000000; font-weight: bold;">Quorum and Adjournment</div>
      <div style="text-align: justify; line-height: 1.25; color: #000000;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="color: #000000;">At least two shareholders who attend the Meeting in person, by </font><font style="color: #252525;">proxy,</font><font style="color: #000000;">&#160;</font>voting




        instruction form <font style="color: #000000;">or by means of voting via the electronic voting system of the Israel Securities Authority (the &#8220;</font><font style="font-weight: bold; color: #000000;">ISA</font><font style="color: #000000;">&#8221; and
          the &#8220;</font><font style="font-weight: bold; color: #000000;">ISA Electronic Voting System</font><font style="color: #000000;">&#8221;) who hold or represent together at least 25% of the voting rights of our issued share capital will constitute a quorum
          for the Meeting. If a quorum is not present within half an hour from the time scheduled for the Meeting, the Meeting will be adjourned to the following week, at the same time and place, without it being necessary to notify our shareholders. A
          quorum at such adjourned meeting shall be any number of participants. </font>Abstentions and &#8220;broker non-votes&#8221;, as well as any abstentions by ADS holders with respect to our <font style="color: #000000;">Ordinary Shares</font> held by BNY
        Mellon, are counted as present and entitled to vote for purposes of determining a legal quorum.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; color: #000000; font-weight: bold;">How You Can Vote</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zdd09aa1352d14f218de44bc0e4769573">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: #000000;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold; font-style: italic;">Voting in person, by written ballot or proxy for holders of Ordinary Shares</font>.&#160; Shareholders<font style="color: #000000;">&#160;</font>registered in the Company&#8217;s shareholders&#8217;
                register in Israel <font style="color: #000000;">entitled to vote at the Meeting may attend the Meeting in person and vote thereat or may vote by written ballot.&#160; </font>In order to attend and vote in person at the Meeting, all such
                shareholders must have a form of government-issued photograph identification (e.g., passport or certificate of incorporation (as the case may be)). A holder of ordinary shares at the end of the trading day on the Record Date shall also be
                entitled to participate in the Meeting by proxy. <font style="color: #000000;">A proxy from the holder of Ordinary Shares must be received by the Company no&#160;later than 3:00 p.m. Israel (8:00 a.m. ET), on August 5, 2023 to be validly
                  included in the tally of Ordinary Shares voted at the Meeting.</font></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <!--PROfilePageNumberReset%Num%2%%%-->
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9b8765b0078646bc9402e71d9cbd635a">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: #000000;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold; font-style: italic;">Shares traded on TASE</font>. A shareholder whose Ordinary Shares are registered with a TASE member may attend the Meeting in person and vote thereat, appoint a proxy or vote by a <font style="color: #000000;">written ballot</font>, by presenting at the Meeting or sending together with the proxy, as the case by may be, an ownership certificate (as of the Record Date) from the applicable TASE member, as required by the
                Israeli Companies Regulations (Proof of Ownership of Shares for Voting at General Meeting) of 2000, as amended (an &#8220;<font style="font-weight: bold;">Ownership Certificate</font>&#8221;).&#160; <font style="color: #000000;">Such Ownership Certificate
                  may be obtained, upon request, at the TASE Member&#8217;s offices or may be sent to the shareholder by mail (subject to payment of the cost of mailing), at the election of the shareholder, on condition that the shareholder&#8217;s request be
                  submitted with respect to a specific securities account.</font></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; margin-left: 54pt; line-height: 1.25; color: #000000;">Shareholders that hold Ordinary Shares through a TASE member, may also vote electronically via the ISA Electronic Voting System after receiving a personal
        identifying number, an access code and additional information regarding the Meeting from the relevant member of the TASE and after carrying out a secured identification process, up to six hours before the time set for the Meeting.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0dc4f5f6ab85442a9eb498e070d0fbe1">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold; font-style: italic;">Voting by voting instruction form for holders of ADSs</font>.&#160; Holders of ADSs (whether registered in their name or in &#8220;street name&#8221;) will receive from BNY Mellon (which acts as the
                Depositary for the ADSs) a voting instruction form in order to instruct their banks, brokers or other nominees on how to vote. For ADSs that are held in &#8220;street name&#8221; through a bank, broker or other nominee, the voting process will be based
                on the underlying beneficial holder of the ADSs directing the bank, broker or other nominee to arrange for BNY Mellon to vote the <font style="color: #000000;">Ordinary Shares</font> represented by the ADSs in accordance with the
                beneficial holder&#8217;s voting instructions. ADS holders should return their BNY Mellon voting instruction form by no later than the date and time set forth on such voting instruction form. <font style="color: #000000;">Under the terms of the
                  Deposit Agreement among the Company, the </font>BNY Mellon<font style="color: #000000;">, as Depositary, and the holders of the Company&#8217;s ADSs, the Depositary shall endeavor (insofar as is practicable and in accordance with the
                  applicable law and the articles of association of the Company) to vote or cause to be voted the number of Ordinary Shares represented by ADSs in accordance with the instructions provided by the holders of ADSs to the Depositary. If
                  no&#160;instructions are received by the Depositary from any holder of ADSs with respect to any of the Ordinary Shares represented by the ADSs evidenced by such holder&#8217;s receipts on or before the date established by the Depositary for such
                  purpose (as set forth above), then the Depositary will deem the holder of the Ordinary Shares to have instructed the Depositary to give a discretionary </font><font style="color: #252525;">proxy</font><font style="color: #000000;"> to a
                  person designated by the Company with respect to the Ordinary Shares represented by such ADSs, and the Depositary will give such instruction. </font>In such case, the restrictions of the Companies Law with respect to &#8220;Personal Interest&#8221;
                as described above, would apply as well.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Vote Required for Approval of the Proposals</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: #000000;">Each outstanding Ordinary Share held by a shareholder is entitled to one vote.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="color: #000000;">Pursuant to the Israeli Companies Law, 1999-5759 (the &#8220;</font><font style="font-weight: bold; color: #000000;">Companies Law</font><font style="color: #000000;">&#8221;), the approval of each of Proposals 1 and 4 requires the affirmative vote of the holders of a majority of the shares (including those represented by ADSs) represented at the Meeting, in person, by </font><font style="color: #252525;">proxy or </font>voting instruction form<font style="color: #000000;">, and voting thereon, or voting via the ISA Electronic Voting System.</font></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Pursuant to Section 272(C1)(1) of the Companies Law, the approval of Proposal 2 requires the affirmative vote of the holders of a majority of the shares (<font style="color: #000000;">including those represented by ADSs) re</font>presented at the Meeting, in person, by proxy<font style="color: #252525;"> or </font>voting instruction form, and voting thereon, or voting via the ISA Electronic Voting System, as long as
        one of the following additional voting requirements is fulfilled (the &#8220;<font style="font-weight: bold;">Disinterested Majority</font>&#8221;):</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb2a7ee5872d34080aa3e7ceef245c519">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the majority of shares (including those represented by ADSs) that voted for the approval of the proposal includes at least a majority of the shares held by non-controlling shareholders and non-interested shareholders voted on the
                proposal at the Meeting, <font style="color: #000000;">in person, by </font><font style="color: #252525;">proxy</font><font style="color: #000000;">, </font>voting instruction form and via the ISA Electronic Voting System (excluding
                abstaining votes); or</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5f0bba62b061418288f3670eac0f3091">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the total number of shares (including those represented by ADSs) of non-controlling shareholders and non-interested shareholders that voted against the approval of the proposal does not exceed two percent of the aggregate voting rights
                in the Company.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">2</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Shareholders and ADS holders are requested to notify us whether or not they have a &#8220;Personal Interest&#8221; in connection with Proposal 2, by indicating on the proxy card or voting
        instruction form or via the ISA Electronic Voting System, or, if voting in person at the Meeting, by informing us prior to voting on the matter at the Meeting. In accordance with the Companies Law, if any shareholder or ADS holder casting a vote in
        connection with Proposal 2 does not so notify us as to whether or not he, she or it has a Personal Interest with respect to Proposal 2, the vote of that shareholder or ADS holder with respect to Proposal 2 will be disqualified and will not be
        counted for purposes of Proposal 2 and in determining whether the above Disinterested Majority approval requirements are satisfied.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under the Companies Law, &#8220;Personal Interest&#8221; is defined as: (1) a shareholder&#8217;s personal interest in the approval of an act or a transaction of the company, including (i) the
        personal interest of his or her relative (which includes for these purposes any spouse, sibling, parent, grandparent or descendant of the shareholder, any descendant, sibling or parent of a spouse of the shareholder and the spouse of any of the
        foregoing); and (ii) a personal interest of a corporate body in which a shareholder or any of his/her aforementioned relatives serves as a director or the chief executive officer, owns at least 5% of its issued share capital or its voting rights or
        has the right to appoint a director or chief executive officer, but (2) excluding a personal interest arising solely from the fact of holding shares in the company. Under the Companies Law, in the case of a person voting by proxy for another
        person, &#8220;Personal Interest&#8221; includes a personal interest of either of the proxy holder or the shareholder granting the proxy, whether or not the proxy holder has discretion how to vote.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">As of the date of this proxy statement, the Company is not aware of any shareholder that would be deemed a controlling shareholder, within the meaning of the Companies Law, for
        purposes of Proposal 2.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The approval of Proposal 3 requires the affirmative vote of the holders of a majority of the shares represented at the Meeting, in person, by proxy <font style="color: #252525;">or




        </font>voting instruction form, and voting thereon, or voting via the ISA Electronic Voting System. In connection with Proposal 3 to approve proposed amendments to the Company&#8217;s Articles of Association in order to include the proposed Special
        Majority Amendment Provision (as such term is defined in Proposal 3) in the Company&#8217;s Articles of Association, such provision must be approved by at least 65% of the holders of the <font style="color: #000000;">Ordinary Shares</font>&#160;<font style="color: #000000;">(including those represented by ADSs) </font>represented at the Meeting, in person or by proxy, voting instruction form, or via the ISA Electronic Voting System, voting on the matter.&#160; Accordingly, if Proposal 3 is
        approved by the shareholders at the Meeting (by a simple majority) but does not receive the affirmative vote of the holders of at least 65% of the <font style="color: #000000;">Ordinary Shares</font>&#160;<font style="color: #000000;">(including those
          represented by ADSs) </font>represented at the Meeting, in person or by proxy, voting instruction form, or via the ISA Electronic Voting System, voting on the matter, the amendments to the Company&#8217;s Articles of Association relating to the
        classification of the Board of Directors shall be approved without the Special Majority Amendment Provision.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Change or Revocation of Vote</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">A holder of ADSs who has executed and returned a voting instruction form or a shareholder who has executed and returned a voting ballot may revoke its voting instructions at any
        time before the applicable deadline by filing with BNY Mellon (in the case of holders of ADSs) or with the Company (in the case of holders of <font style="color: #000000;">Ordinary Shares</font>) a written notice of revocation or a duly executed
        voting instruction form or voting slip (as applicable) bearing a later date. If your ADSs are held in &#8220;street name,&#8221; you may change your vote by submitting new voting instructions to your broker, bank, trustee, or nominee or, if you have obtained a
        legal proxy from your broker, bank, trustee or nominee giving you the right to vote your shares, by attending the Meeting and voting in person.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="color: #000000;">If you are a shareholder of record, you may change your mind and cancel your </font><font style="color: #252525;">proxy</font><font style="color: #000000;"> card by filing a written notice of revocation with the Company, by completing and returning a duly executed </font><font style="color: #252525;">proxy</font><font style="color: #000000;"> card bearing a later date or by voting in
          person at the Meeting. Attendance at the Meeting will not in and of itself constitute revocation of </font><font style="color: #252525;">proxy</font><font style="color: #000000;">.</font></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If you are a beneficial owner of shares registered in the name of a member of the TASE, you may change your vote (i) by attending the Meeting and voting in person, by presenting
        a valid Ownership Certificate as of the Record Date; (ii) by delivering a later-dated duly executed proxy, together with a valid Ownership Certificate as of the Record Date, to the Company&#8217;s registered office in Israel at least 48 hours prior to
        the designated time for the Meeting, or (iii) by following the relevant instructions for changing your vote via the ISA Electronic Voting System by no later than six hours before the time set for the Meeting.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Solicitation of Proxies</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We may bear the reasonable and actual cost of solicitation of proxies, including preparation, assembly, printing, and mailing of the BNY Mellon voting instruction form and any
        additional information furnished to beneficial ordinary shareholders or beneficial holders of ADSs. The Notice of Annual General Meeting of the Shareholders, the Proxy Statement, and the proxy card will not be mailed to beneficial ordinary
        shareholders in Israel. We may reimburse brokerage firms and other persons representing beneficial owners of <font style="color: #000000;">Ordinary Shares</font> or ADSs only for reasonable expenses incurred by them in forwarding proxy soliciting
        materials to such beneficial owners and to the extent such costs were actually incurred by such holders of ADSs in street name. In addition to solicitation by mail, certain of our directors, officers and employees, without additional remuneration,
        may solicit proxies by telephone, facsimile, email or personal contact.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">3</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Position Statements</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="color: #000000;">Shareholders are permitted to express their position on the proposals to be voted on at the Meeting by submitting a written statement, through the
          Company, to the other shareholders (a &#8220;</font><font style="font-weight: bold; color: #000000;">Position Statement</font><font style="color: #000000;">&#8221;). Position Statements should be submitted to the Company at its registered offices at 2
          HaMa&#8217;ayan Street, Modi&#8217;in 7177871, Israel, Attn: Chief Financial Officer. Any Position Statement received will be furnished to the SEC in a Report of Foreign Private Issuer on Form 6-K and will be made available to the public on the SEC&#8217;s website
          at </font><font style="color: #0563C1;"><u>http://www.sec.gov</u></font><font style="color: #000000;">, and in addition at </font><font style="color: #0563C1;"><u>http://www.magna.isa.gov.il</u></font><font style="color: #000000;"> or </font><font style="color: #0563C1;"><u>http://maya.tase.co.il</u></font><font style="color: #000000;">. Position Statements must be submitted no later than 3:00 p.m. (Israel time) on July 28, 2023.</font></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: #000000;">Each member of the TASE is required to e-mail a link to the Proxy Statement and any Position Statements published on the websites of the TASE and the ISA
        (http://www.tase.co.il/tase/ and http://www.magna.isa.gov.il, respectively) to each shareholder who is not listed in the Company&#8217;s shareholder register and whose shares are held through the TASE member; except in cases in which a shareholder has
        notified the TASE member that he/she/it is not interested in receiving such links and has submitted the notice (a) with respect to a specific securities account, and (b) prior to the Record Date.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: #000000;">The&#160;last date for submitting a request to include a proposal in accordance with Section 66(b) of the Israeli Companies Law, 5759-1999, is June 30, 2023.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">BENEFICIAL OWNERSHIP OF DIRECTORS AND OFFICERS</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="color: #000000;">The following table sets forth information regarding the beneficial ownership of our outstanding Ordinary Shares as of June 20, 2023 of each of
            our directors and executive officers individually and as a group.&#160; The percentages shown are based on 922,958,942 Ordinary Shares issued and outstanding as of June 20, 2023.</font><font style="font-size: 12pt;">&#160;</font><font style="color: #000000;">Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting power or investment power with respect to securities. All ordinary shares subject to options currently exercisable or exercisable
            into ordinary shares within 60 days of June 20, 2023, and underlying performance stock units (&#8220;</font><font style="font-weight: bold; color: #000000;">PSUs</font><font style="color: #000000;">&#8221;) that shall vest within 60 days of June 20, 2023,
            are deemed to be outstanding and beneficially owned by the shareholder holding such options or PSUs for the purpose of computing the number of shares beneficially owned by such shareholder. Such shares are also deemed outstanding for purposes
            of computing the percentage ownership of the person holding the optionor PSU. They are not, however, deemed to be outstanding and beneficially owned for the purpose of computing the percentage ownership of any other shareholder.</font></div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25; color: #000000;">&#160;</div>
      </div>
      <table cellspacing="0" cellpadding="0" class="cfttable" id="za66401602d3541658499eb07e06580fa" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">

          <tr>
            <td valign="bottom" style="vertical-align: bottom;">
              <div style="line-height: 1.25; color: #000000;">&#160;</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: bottom;">
              <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">Number of</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom;">
              <div style="line-height: 1.25; color: #000000;">&#160;</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: bottom;">
              <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">Ordinary Shares</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom;">
              <div style="line-height: 1.25; color: #000000;">&#160;</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: bottom;">
              <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">Beneficially</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: bottom;">
              <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">Percent of</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">
              <div style="line-height: 1.25; color: #000000;">&#160;</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;"> Held</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">Class</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom;">
              <div style="line-height: 1.25; color: #000000;">&#160;</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;">
              <div style="line-height: 1.25; color: #000000; font-weight: bold;">Directors</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom;">
              <div style="line-height: 1.25; color: #000000;">&#160;</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF; width: 76%;">
              <div style="line-height: 1.25; color: #000000;">Aharon Schwartz<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25; color: #000000;">4,515,000</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25; color: #000000;">*</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%;">
              <div style="line-height: 1.25; color: #000000;">Michael J. Anghel<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25; color: #000000;">810,000</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25; color: #000000;">*</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF; width: 76%;">
              <div style="line-height: 1.25; color: #000000;">B.J. Bormann<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup></div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25; color: #000000;">810,000</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25; color: #000000;">*</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%;">
              <div style="line-height: 1.25; color: #000000;">Rami Dar<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(4)</sup></div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25; color: #000000;">360,000</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF; width: 76%;">
              <div style="line-height: 1.25; color: #000000;">Raphael Hofstein<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(5)</sup></div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25; color: #000000;">810,000</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25; color: #000000;">*</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%;">
              <div style="line-height: 1.25; color: #000000;">Avraham Molcho<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(6)</sup></div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25; color: #000000;">810,000</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25; color: #000000;">*</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF; width: 76%;">
              <div style="line-height: 1.25; color: #000000;">Sandra Panem<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(7)</sup></div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25; color: #000000;">810,000</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25; color: #000000;">*</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%;">
              <div style="line-height: 1.25; color: #000000;">&#160;</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF; width: 76%;">
              <div style="line-height: 1.25; color: #000000; font-weight: bold;">Executive Officers</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%;">
              <div style="line-height: 1.25; color: #000000;">&#160;</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF; width: 76%;">
              <div style="line-height: 1.25; color: #000000;">Philip A. Serlin<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(8)</sup></div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25; color: #000000;">8,618,215</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25; color: #000000;">*</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%;">
              <div style="line-height: 1.25; color: #000000;">Mali Zeevi<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(9)</sup></div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25; color: #000000;">2,528,415</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25; color: #000000;">*</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF; width: 76%;">
              <div style="line-height: 1.25; color: #000000;">Ella Sorani<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(10)</sup></div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25; color: #000000;">2,354,290</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25; color: #000000;">*</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%;">
              <div style="line-height: 1.25; color: #000000;">Tami Rachmilewitz, M.D.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(11)</sup></div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25; color: #000000;">-</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25; color: #000000;">*</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 76%;">
              <div style="line-height: 1.25; color: #000000;">Holly May&#160;<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(12)</sup></div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25; color: #000000;">1,284,900</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25; color: #000000;">*</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%;">
              <div style="line-height: 1.25; color: #000000;">Adam Janoff<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(13)</sup></div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25; color: #000000;">-</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25; color: #000000;">*</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF; width: 76%;">
              <div style="line-height: 1.25; color: #000000; font-weight: bold;">All directors and executive officers as a group (13 persons)<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(14)</sup></div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25; color: #000000;">23,710,820</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25; color: #000000;">2.5</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25; color: #000000;">%</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="line-height: 1.25; color: #000000;">* Less than 1%</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">4</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z9392e95e0dba43fa9b95e1f1545d4c13">

          <tr>
            <td style="width: 3%; vertical-align: top;">
              <div style="line-height: 1.25; color: #000000;">(1)</div>
            </td>
            <td style="width: 97%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; color: #000000;">Includes 3,705,000 Ordinary Shares and 810,000 Ordinary Shares issuable upon exercise of outstanding options currently exercisable or exercisable within 60 days of June 20,
                2023. Does not include 720,000 Ordinary Shares issuable upon exercise of outstanding options that are not exercisable within 60 days of June 20, 2023.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25; color: #000000;">&#160;</div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zd51d1b724bf8428e94a0543ff42a5063">

          <tr>
            <td style="width: 3%; vertical-align: top;">
              <div style="line-height: 1.25; color: #000000;">(2)</div>
            </td>
            <td style="width: 97%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; color: #000000;">Includes 810,000 Ordinary Shares issuable upon exercise of outstanding options currently exercisable or exercisable within 60 days of June 20, 2023. Does not include 720,000
                Ordinary Shares issuable upon exercise of outstanding options that are not exercisable within 60 days of June 20, 2023.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25; color: #000000;">&#160;</div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zb04c999fdaaf43f9a47f0bac1c330914">

          <tr>
            <td style="width: 3%; vertical-align: top;">
              <div style="line-height: 1.25; color: #000000;">(3)</div>
            </td>
            <td style="width: 97%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; color: #000000;">Includes 810,000 Ordinary Shares issuable upon exercise of outstanding options currently exercisable or exercisable within 60 days of June 20, 2023. Does not include 720,000
                Ordinary Shares issuable upon exercise of outstanding options that are not exercisable within 60 days of June 20, 2023.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25; color: #000000;">&#160;</div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z9c101cbc4c50434782d0ab36819e1d5b">

          <tr>
            <td style="width: 3%; vertical-align: top;">
              <div style="line-height: 1.25; color: #000000;">(4)</div>
            </td>
            <td style="width: 97%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; color: #000000;">Includes 360,000 Ordinary Shares issuable upon exercise of outstanding options currently exercisable or exercisable within 60 days of June 20, 2023. Does not include 720,000
                Ordinary Shares issuable upon exercise of outstanding options that are not exercisable within 60 days of June 20, 2023.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25; color: #000000;">&#160;</div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z32c890eac04f45cea70d8ca36524514a">

          <tr>
            <td style="width: 3%; vertical-align: top;">
              <div style="line-height: 1.25; color: #000000;">(5)</div>
            </td>
            <td style="width: 97%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; color: #000000;">Includes 810,000 Ordinary Shares issuable upon exercise of outstanding options currently exercisable or exercisable within 60 days of June 20, 2023. Does not include 720,000
                Ordinary Shares issuable upon exercise of outstanding options that are not exercisable within 60 days of June 20, 2023.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25; color: #000000;">&#160;</div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zb555d6f81733439880ebd680add145bd">

          <tr>
            <td style="width: 3%; vertical-align: top;">
              <div style="line-height: 1.25; color: #000000;">(6)</div>
            </td>
            <td style="width: 97%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; color: #000000;">Includes 810,000 Ordinary Shares issuable upon exercise of outstanding options currently exercisable or exercisable within 60 days of June 20, 2023. Does not include 720,000
                Ordinary Shares issuable upon exercise of outstanding options that are not exercisable within 60 days of June 20, 2023.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25; color: #000000;">&#160;</div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zd93e49ab205a44a0993292c45378e662">

          <tr>
            <td style="width: 3%; vertical-align: top;">
              <div style="line-height: 1.25; color: #000000;">(7)</div>
            </td>
            <td style="width: 97%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; color: #000000;">Includes 810,000 Ordinary Shares issuable upon exercise of outstanding options currently exercisable or exercisable within 60 days of June 20, 2023. Does not include 720,000
                Ordinary Shares issuable upon exercise of outstanding options that are not exercisable within 60 days of June 20, 2023.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25; color: #000000;">&#160;</div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zec8f6f2505a547578219324f70a51b4a">

          <tr>
            <td style="width: 3%; vertical-align: top;">
              <div style="line-height: 1.25; color: #000000;">(8)</div>
            </td>
            <td style="width: 97%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; color: #000000;">Includes 171,918 Ordinary Shares and 8,446,297 Ordinary Shares issuable upon exercise of outstanding options and PSUs currently exercisable or exercisable within 60 days of
                June 20, 2023. Does not include 6,989,119 Ordinary Shares issuable upon exercise of outstanding options and PSUs that are not exercisable within 60 days of June 20, 2023.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25; color: #000000;">&#160;</div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zfd3873b97cdf44f496df40301a954356">

          <tr>
            <td style="width: 3%; vertical-align: top;">
              <div style="line-height: 1.25; color: #000000;">(9)</div>
            </td>
            <td style="width: 97%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; color: #000000;">Includes 328,684 Ordinary Shares and 2,199,731 Ordinary Shares issuable upon exercise of outstanding options and PSUs currently exercisable or exercisable within 60 days of
                June 20, 2023. Does not include 4,783,369 Ordinary Shares issuable upon exercise of outstanding options and PSUs that are not exercisable within 60 days of June 20, 2023.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25; color: #000000;">&#160;</div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zbf095da7f9a642068a73f125817558cf">

          <tr>
            <td style="width: 3%; vertical-align: top;">
              <div style="line-height: 1.25; color: #000000;">(10)</div>
            </td>
            <td style="width: 97%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; color: #000000;">Includes 66,150 Ordinary Shares and 2,288,140 Ordinary Shares issuable upon exercise of outstanding options and PSUs currently exercisable or exercisable within 60 days of
                June 20, 2023. Does not include 4,783,369 Ordinary Shares issuable upon exercise of outstanding options and PSUs that are not exercisable within 60 days of June 20, 2023.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25; color: #000000;">&#160;</div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z9393cf62eb3b41a19bdec96da7785354">

          <tr>
            <td style="width: 3%; vertical-align: top;">
              <div style="line-height: 1.25; color: #000000;">(11)</div>
            </td>
            <td style="width: 97%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; color: #000000;">Does not include 1,740,000 Ordinary Shares issuable upon exercise of outstanding options and PSUs that are not exercisable within 60 days of June 20, 2023.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25; color: #000000;">&#160;</div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="za7efe5c943654b1ca81b60594a1e0ad2">

          <tr>
            <td style="width: 3%; vertical-align: top;">
              <div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">(12)</div>
            </td>
            <td style="width: 97%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">Includes 1,284,900 Ordinary Shares issuable upon exercise of outstanding options currently exercisable or exercisable within
                60 days of June 20, 2023. Does not include 9,335,610 Ordinary Shares issuable upon exercise of outstanding options and PSUs that are not exercisable within 60 days of June 20, 2023.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top;">&#160;</td>
            <td style="width: 97%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top;">
              <div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">(13)</div>
            </td>
            <td style="width: 97%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">Does not include 1,335,000 Ordinary Shares issuable upon exercise of outstanding equity instruments that are not exercisable
                within 60 days of June 20, 2023.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top;">
              <div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">&#160;</div>
            </td>
            <td style="width: 97%; vertical-align: top;">
              <div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top;">
              <div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">(14)</div>
            </td>
            <td style="width: 97%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">See footnotes (1)-(13) for certain information regarding beneficial ownership.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">5</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">DIVERSITY OF THE BOARD OF DIRECTORS</div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25; color: #000000; font-style: italic; font-weight: bold;">&#160;</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">Board Diversity Matrix (As of June 20, 2023)</div>
        <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">&#160;</div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z26502ad35ee04f849168463a0fc7a153">

          <tr>
            <td style="width: 48.62%; vertical-align: top;">
              <div style="line-height: 1.25;">Country of Principal Executive Offices</div>
            </td>
            <td style="width: 5.56%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">&#160;</div>
            </td>
            <td colspan="7" style="width: 45.83%; vertical-align: top;">
              <div style="line-height: 1.25;">Israel</div>
            </td>
          </tr>
          <tr>
            <td style="width: 48.62%; vertical-align: top;">
              <div style="line-height: 1.25;">Foreign Private Issuer</div>
            </td>
            <td style="width: 5.56%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">&#160;</div>
            </td>
            <td colspan="7" style="width: 45.83%; vertical-align: top;">
              <div style="line-height: 1.25;">Yes</div>
            </td>
          </tr>
          <tr>
            <td style="width: 48.62%; vertical-align: top;">
              <div style="line-height: 1.25;">Disclosure Prohibited under Home Country Law</div>
            </td>
            <td style="width: 5.56%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">&#160;</div>
            </td>
            <td colspan="7" style="width: 45.83%; vertical-align: top;">
              <div style="line-height: 1.25;">No</div>
            </td>
          </tr>
          <tr>
            <td style="width: 48.62%; vertical-align: top;">
              <div style="line-height: 1.25;">Total Number of Directors</div>
            </td>
            <td style="width: 5.56%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">&#160;</div>
            </td>
            <td colspan="7" style="width: 45.83%; vertical-align: top;">
              <div style="line-height: 1.25; color: #000000; font-weight: bold;">7</div>
            </td>
          </tr>
          <tr>
            <td style="width: 48.62%; vertical-align: top;">
              <div style="line-height: 1.25; font-weight: bold;">Part I: Gender Identity</div>
            </td>
            <td style="width: 5.56%; vertical-align: bottom;">
              <div style="text-align: center; line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 9.72%; vertical-align: bottom; border-bottom: #000000 2px solid;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Female</div>
            </td>
            <td style="width: 2.77%; vertical-align: bottom;">
              <div style="text-align: center; line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.34%; vertical-align: bottom; border-bottom: #000000 2px solid;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Male</div>
            </td>
            <td style="width: 2.77%; vertical-align: bottom;">
              <div style="text-align: center; line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.34%; vertical-align: bottom; border-bottom: #000000 2px solid;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Non-Binary</div>
            </td>
            <td style="width: 2.77%; vertical-align: bottom;">
              <div style="text-align: center; line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 11.11%; vertical-align: bottom; border-bottom: #000000 2px solid;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Did Not Disclose&#8194;</div>
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Gender</div>
            </td>
          </tr>
          <tr>
            <td style="width: 48.62%; vertical-align: top;">
              <div style="line-height: 1.25;">Directors</div>
            </td>
            <td style="width: 5.56%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 9.72%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">2</div>
            </td>
            <td style="width: 2.77%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.34%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">5</div>
            </td>
            <td style="width: 2.77%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 8.34%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">0</div>
            </td>
            <td style="width: 2.77%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 11.11%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">0</div>
            </td>
          </tr>
          <tr>
            <td style="width: 48.62%; vertical-align: top;">
              <div style="line-height: 1.25; font-weight: bold;">Part II: Demographic Background</div>
            </td>
            <td style="width: 5.56%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">&#160;</div>
            </td>
            <td colspan="7" style="width: 45.83%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">&#8195;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 48.62%; vertical-align: top;">
              <div style="line-height: 1.25;">Underrepresented Individual in Home Country Jurisdiction</div>
            </td>
            <td style="width: 5.56%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">&#160;</div>
            </td>
            <td colspan="7" style="width: 45.83%; vertical-align: bottom;">
              <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">0</div>
            </td>
          </tr>
          <tr>
            <td style="width: 48.62%; vertical-align: top;">
              <div style="line-height: 1.25;">LGBTQ+</div>
            </td>
            <td style="width: 5.56%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">&#160;</div>
            </td>
            <td colspan="7" style="width: 45.83%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">0</div>
            </td>
          </tr>
          <tr>
            <td style="width: 48.62%; vertical-align: top;">
              <div style="line-height: 1.25;">Did Not Disclose Demographic Background</div>
            </td>
            <td style="width: 5.56%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">&#160;</div>
            </td>
            <td colspan="7" style="width: 45.83%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">0</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">EXECUTIVE OFFICER COMPENSATION</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">For information regarding the compensation incurred by the Company in relation to our <font style="color: #000000;">five most highly compensated office holders (within the
          meaning of the Israeli Companies Law)</font> for the year ended December 31, 2022, see &#8220;Item 6B. Compensation &#8212; Compensation of Directors and Senior Management&#8221; of the Company&#8217;s Annual Report on Form 20-F, which was filed on March 22, 2023.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">PROPOSAL 1</div>
      <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">RE-ELECTION OF NON-EXTERNAL DIRECTORS</div>
      <div style="text-align: center; line-height: 1.25; color: #000000;">(Item 1 on the Proxy Card)</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; color: #000000; font-weight: bold;">Background</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: #000000;">Our Articles of Association specify that the number of directors will be at least five but not more than ten. The current Board of Directors consists of seven
        members (including two external directors, within the meaning of the Companies Law.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="color: #000000;">Our Board of Directors has nominated the persons named below for re-election to the Board of Directors, to serve as non-external directors until the
          next Annual General Meeting of our shareholders </font>and until their respective successors are duly elected and qualified<font style="color: #000000;">. However, if Proposal 3 is approved at the Meeting and our shareholders approve an
          amendment to the Company&#8217;s Articles of Association to classify the Board of Directors, then the non-external director nominees, subject to their individual election at the Meeting, will be separated into three different classes and elections for
          each class will be staggered across a three-year period.&#160; For more information, please see Proposal 3 below.</font></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We are not aware of any reason why the nominees, if elected, would be unable or unwilling to serve as directors.&#160; <font style="color: #000000;">If any of such directors is
          unable to serve, the persons named in the </font><font style="color: #252525;">proxy</font><font style="color: #000000;"> shall vote the Ordinary Shares for the election/re-election of such other nominee/director as the Board of Directors may
          propose. The following nominees have advised the Company that they will serve as directors upon election.</font></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: #000000;">The following provides certain relevant information concerning the directors, including their principal occupations during at least the past five years.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="za504ad11d1dc46799b0192799fa702c0">

          <tr>
            <td style="width: 20%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; color: #000000;"><u>Director</u></div>
            </td>
            <td style="width: 6%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; color: #000000;"><u>Age</u></div>
            </td>
            <td style="width: 74%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; color: #000000;"><u>Principal Occupation</u></div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 20%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 6%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 74%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 20%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; color: #000000;">Aharon Schwartz, Ph.D.</div>
            </td>
            <td style="width: 6%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; color: #000000;">80</div>
            </td>
            <td style="width: 74%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; color: #000000;">Dr. Schwartz has served as the Chairman of our Board of Directors since 2004. Dr. Schwartz served in a number of positions in Teva from 1975 through 2011, the most recent
                being Vice President, Head of Teva Innovative Ventures from 2008. Dr. Schwartz is currently a member of the board of directors of Protalix Ltd. (NYSE American:PLX), and also works as an independent consultant. Dr. Schwartz received his
                Ph.D. in organic chemistry from the Weizmann Institute, his M.Sc. degree in organic chemistry from the Technion &#8211; Institute of Technology and a B.Sc. degree in chemistry and physics from the Hebrew University of Jerusalem. In addition, Dr.
                Schwartz holds a Ph.D. from the Hebrew University of Jerusalem in the history and philosophy of science.</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">6</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 20%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; color: #000000;">Michael Anghel, Ph.D.</div>
            </td>
            <td style="width: 6%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; color: #000000;">84</div>
            </td>
            <td style="width: 74%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; color: #000000;">Dr. Anghel&#160;has served on our Board of Directors since 2010 and on our Investment Monitoring Committee since 2010. From 1977 to 1999, Dr. Anghel led the Discount Investment
                Corporation Ltd. (of the IDB Group) activities in the fields of technology and communications. Dr. Anghel was instrumental in founding Tevel, one of the first Israeli cable television operators and later in founding Cellcom Israel Ltd.
                (NYSE:CEL), the second Israeli cellular operator. In 1999, he founded CAP Ventures, an advanced technology investment company. From 2004 to 2005, Dr. Anghel served as chief executive officer of Discount Capital Markets, the investment
                banking arm of the Israel Discount Bank (TASE:DSCT). Over the years, Dr. Anghel has been involved in founding and managing various technology enterprises and has served on the boards of directors of various major Israeli corporations and
                financial institutions, many of them publicly traded in the U.S. and Israel. During the past two years, Dr. Anghel completed long term tenures as director on the boards of: Partner Communications Company, Ltd. (Nasdaq:PTNR, TASE:PTNR),
                Strauss Group Ltd. (TASE:STRS), and Orbotech Ltd. (Nasdaq:ORBK).&#160; Dr. Anghel currently serves as director on the board of directors of InMode Ltd. (Nasdaq:INMD) and Ellomay Capital Ltd. (NYSE American: ELLO). Prior to launching his business
                career, Dr. Anghel served as a full-time member of the faculty of the Recanati Graduate School of Business Administration of the Tel Aviv University, where he taught finance and corporate strategy. Until recently, Dr. Anghel served as
                Chairman of the Tel Aviv University&#8217;s Executive Program. Dr. Anghel holds a B.A. degree (Economics) from the Hebrew University of Jerusalem and an MBA degree and Ph.D. (Finance) from Columbia University, New York.</div>
              <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
            </td>
          </tr>
          <tr>
            <td style="width: 20%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; color: #000000;">B.J. Bormann, Ph.D.</div>
            </td>
            <td style="width: 6%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; color: #000000;">64</div>
            </td>
            <td style="width: 74%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; color: #000000;">Dr. Bormann has served on our Board of Directors since August 2013 and on our Compensation Committee since 2022. Dr. Bormann currently serves as the Vice President of
                Translational Science and Network Alliances at The Jackson Laboratory, a non-profit organization focused on the genetic basis of disease. Dr. Bormann was previously the Chief Executive Officer of Supportive Therapeutics, LLC, a Boston based
                company that is developing two molecules for use in the supportive care of oncology patients. In the past several years Dr. Bormann has held executive positions in several biotechnology companies including NanoMedical Systems (Austin,
                Texas), Harbour Antibodies (Rotterdam, The Netherlands) and Pivot Pharmaceuticals (PVTF: OTC listed). Prior to these engagements, Dr. Bormann was Senior Vice President responsible for world-wide alliances, licensing and business development
                at Boehringer Ingelheim Pharmaceuticals, Inc. from 2007 to 2013. From 1996 to 2007, Dr. Bormann served in a number of positions at Pfizer, Inc., the last one being Vice President of Pfizer Global Research and Development and world-wide Head
                of Strategic Alliances. Dr. Bormann serves on the board of directors of various companies, including Xeris BioPharma, Inc (Nasdaq:XERS) and NanoMedical Systems (private). Dr. Bormann received her Ph.D. in biomedical science from the
                University of Connecticut Health Center and her B.Sc. degree from Fairfield University in biology. Dr. Bormann completed postdoctoral training at Yale Medical School in the department of pathology.&#160;</div>
              <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
            </td>
          </tr>
          <tr>
            <td style="width: 20%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; color: #000000;">Raphael Hofstein, Ph.D.</div>
            </td>
            <td style="width: 6%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; color: #000000;">73</div>
            </td>
            <td style="width: 74%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; color: #000000;">Dr. Hofstein has served on our Board of Directors since 2003, our Audit Committee since 2007 and our Compensation Committee since 2012. Dr. Hofstein has served as the
                President and Chief Executive Officer of MaRS Innovation (a commercialization company for 15 of Toronto&#8217;s universities, institutions and research institutes plus the MaRS Discovery District) from June 2009 to March 2020. From 2000 through
                June 2009, Dr. Hofstein was the President and Chief Executive Officer of Hadasit Medical Research Services and Development Ltd., or Hadasit, the technology transfer company of Hadassah University Hospitals. Dr. Hofstein has served as
                chairman of the board of directors of Hadasit since 2006. Prior to joining Hadasit, Dr. Hofstein was the President of Mindsense Biosystems Ltd. and the Business Unit Director of Ecogen Inc. and has held a variety of other positions,
                including manager of R&amp;D and chief of immunochemistry at the International Genetic Science Partnership. Dr. Hofstein serves on the board of directors of numerous companies. Dr. Hofstein received his Ph.D. and M.Sc. from the Weizmann
                Institute of Science, and his B.Sc. degree in chemistry and physics from the Hebrew University of Jerusalem. Dr. Hofstein completed postdoctoral training at Harvard Medical School in both the departments of biological chemistry and
                neurobiology.&#160;</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">7</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 20%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; color: #000000;">Sandra Panem, Ph.D.</div>
            </td>
            <td style="width: 6%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; color: #000000;">76</div>
            </td>
            <td style="width: 74%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; color: #000000;">Dr. Panem has served on our Board of Directors since 2014.&#160; Dr. Panem is currently co-founder and President of NeuroNetworksFund, a not-for-profit venture capital fund
                focusing on epilepsy, schizophrenia and autism. From 2000 to 2022, Dr. Panem was managing partner at Cross Atlantic Partners. From 1994 to 1999, Dr. Panem was President of Vector Fund Management, the then asset management affiliate of
                Vector Securities International. Prior thereto, Dr. Panem served as Vice President and Portfolio Manager for the Oppenheimer Global BioTech Fund, a mutual fund that invested in public and private biotechnology companies. Previously, Dr.
                Panem was Vice President at Salomon Brothers Venture Capital, a fund focused on early and later-stage life sciences and technology investments. Dr. Panem was also a Science and Public Policy Fellow in economic studies at the Brookings
                Institution, and an Assistant Professor of Pathology at the University of Chicago. Dr. Panem currently serves on the board of directors of Acorda Therapeutics, Inc. (Nasdaq:ACOR). Previously, Dr. Panem served on numerous boards of public
                and private companies, including Martek Biosciences (Nasdaq:MATK), IBAH Pharmaceuticals (Nasdaq:IBAH), Confluent Surgical, Molecular Informatics and Labcyte, Inc. She received a B.S. degree in biochemistry and a Ph.D. in microbiology from
                the University of Chicago.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="color: #000000;">Each director has attested to the Board of Directors and the Company that he or she meets all the requirements in connection with the election of
          directors of publicly traded companies under the Companies Law </font>and that he/she possesses the necessary qualifications and is able to dedicate sufficient time to fulfill his/her duties as a director of our Company, taking into
        consideration our Company&#8217;s size and special needs<font style="color: #000000;">.</font></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If re-elected at the Meeting, each of the non-external director nominees shall continue to be entitled to the same cash compensation approved by the shareholders at our annual
        general meeting held in 2022, of $30,000 per annum, $1,200 for each board or committee meeting attended in person, $720 for each board or committee meeting attended via telephone or videoconference, $600 for participation by written consent and
        $3,000 for membership of each committee of the Board of Directors, and in the case of the Chairman of the Board of Directors, such fees in amounts that are 50% higher than the foregoing fees, in each case provided that such fees do not exceed the
        maximum amounts payable to external directors from time to time by us under the Israeli Companies Regulations (Rules Regarding Compensation and Expense Reimbursement of External Directors), 2000 and the Israeli Companies Regulations (Relief for
        Companies who Securities are Listed for Trading Outside of Israel), 2000.&#160; If re-elected as non-external directors at the Meeting, the approval of the re-election of the non-external director nominees will be deemed to be an approval of the
        foregoing cash compensation.&#160; In addition, if re-elected at this Meeting, each director will continue to be party to an indemnification agreement with the Company in the form of indemnification letter previously approved by the shareholders on
        November 17, 2011 to be entered into by the Company with directors serving from time to time in such capacity and shall continue to be insured under the Company&#8217;s directors&#8217; and officers&#8217; liability insurance coverage policy, as in effect from time
        to time, which provides coverage for all directors of the Company.</div>
      <div style="text-align: justify; line-height: 1.25; color: #000000;">&#160;</div>
      <div style="line-height: 1.25; color: #000000; font-weight: bold;">Proposal</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The <font style="color: #000000;">shareholders</font> are being asked to re-elect the non-external director nominees named above, each to serve as members of our Board of
        Directors until our next annual general meeting of shareholders and until their respective successors are duly elected and qualified, <font style="color: #000000;">or each to serve for staggered terms ending at the 2024, 2025 and 2026 annual </font>general




        <font style="color: #000000;">meetings </font>of shareholders<font style="color: #000000;">, if Proposal 3 is approved at the Meeting.&#160; </font>Each director nominee shall be voted on separately.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; color: #000000; font-weight: bold;">Approval Required</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-indent: 36pt; line-height: 1.25; color: #000000;">See &#8220;Vote Required for Approval of the Proposals&#8221; above.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; color: #000000; font-weight: bold;">Board Recommendation</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: #000000; font-weight: bold;">Our Board of Directors recommends a vote &#8220;FOR&#8221; the re-election of each of the non-external director nominees named above.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">8</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">PROPOSAL 2</div>
      <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">APPROVAL OF EQITY COMPENSATION OF PHILIP SERLIN, CHIEF EXECUTIVE OFFICER</div>
      <div style="text-align: center; line-height: 1.25; color: #000000;">(Item 2 on the Proxy Card)</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; color: #000000; font-weight: bold;">Background</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">Philip Serlin has served as the Company&#8217;s Chief Executive Officer since October 2016. Prior to becoming our Chief Executive Officer, Mr. Serlin served as our Chief Financial
        and Operating Officer beginning in 2009. Pursuant to the Companies Law, arrangements regarding the compensation of the Company&#8217;s Chief Executive Officer require the approval of the Compensation Committee, the Board of Directors, and the
        shareholders by the Disinterested Majority, in that order.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Grant of Options and Performance Stock Units</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">Our <font style="color: #000000;">2003 Share</font> Incentive Plan <font style="color: #000000;">provides for the grant of equity compensation to our officers in the form of
          options to purchase Ordinary Shares and PSUs, among other instruments. Equity-based compensation is intended to reward for future performance and is used to foster a long-term link between our officers&#8217; interests and the interests of the Company
          and its shareholders as well as to attract, motivate and retain officers for the long term. Options create a direct link to share performance, compensating officers if the price of our Ordinary Shares rises in relation to the exercise price of
          the options. PSUs, the vesting of which is based on pre-determined, significant Company business milestones, are intended to attract, motivate and retain officers by linking compensation closely to Company performance.</font></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;"><font style="color: #000000;">Following approval by our Compensation Committee, our Board of Directors approved, subject to shareholder approval, the grant to Mr. Serlin of
          options to purchase 4,495,300 of our Ordinary Shares (equivalent to 299,687 of our ADSs). The exercise price of the options is NIS 0.163 per share (equivalent to $0.68</font><font style="font-weight: bold; color: #000000;">&#160;</font><font style="color: #000000;">per ADS), which is equal to </font>the closing price of the Ordinary Shares on the TASE on the date the option grant was approved by the Board. The options will vest over a period of four years (25% after one year, 6.25%
        each quarter thereafter) from the date the grant was approved by the Board, for so long as Mr. Serlin continues to serve as an employee of the Company at the time of vesting. The options shall expire 10 years after the date of grant.&#160; The grant to
        Mr. Serlin contains provisions for the acceleration of the vesting of the options on the occurrence of both (i) a change of control of the Company (as will be defined in Mr. Serlin&#8217;s option agreement) and (ii) following such change of control,
        either the termination of Mr. Serlin&#8217;s employment by the Company or a significant demotion in his new job or position.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">In addition, following approval by our Compensation Committee, our Board of Directors approved, subject to shareholder approval, the grant to Mr. Serlin of 4,064,800 PSUs <font style="color: #000000;">(equivalent of 270,987 ADSs)</font>. It is the view of our Board of Directors that a significant portion of the equity compensation of our officers should be aligned with performance, and therefore the proposed grant of
        PSUs to Mr. Serlin constitutes 47% of the total proposed equity compensation. The vesting of such PSUs will occur if the Company achieves certain strategic milestones over the next several years that have been determined by the Compensation
        Committee and Board of Directors.&#160; The PSUs shall expire 10 years after the date of grant.&#160; The grant to Mr. Serlin contains provisions for the acceleration of the vesting of the PSUs that are identical to those included in his option grant, as
        described above.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">The Compensation Committee and the Board of Directors have determined that the equity compensation described above is (i) in the best interest of the Company, (ii) in
        accordance with our Compensation Policy and (iii) reasonable and appropriate in light of Mr. Serlin&#8217;s role as chief Executive Officer, his qualifications and experience and his past and anticipated contributions to the advancement of the Company&#8217;s
        activities. As of the date of this proxy statement, Mr. Serlin is the beneficial owner (as defined in SEC rules) of 8,618,215 Ordinary Shares (equivalent of 574,548 ADSs) (approximately 0.91% of the Company&#8217;s outstanding shares), all of which are
        subject to options and PSUs, currently exercisable or <font style="color: #000000;">exercisable within 60 days</font>. For additional information regarding Mr. Serlin&#8217;s beneficial ownership of our Ordinary Shares, see above &#8220;Beneficial Ownership
        of Directors and Officers.&#8221; The total fair value of Mr. Serlin&#8217;s proposed equity compensation does not exceed the limits provided for in our Compensation Policy and the proposed options and PSUs and their terms are consistent with our Compensation
        Policy.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">9</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Proposal</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">It is therefore proposed that at the Meeting the following resolution be adopted:</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: -0.55pt; margin-left: 36pt; line-height: 1.25; font-weight: bold;">&#8220;RESOLVED, to approve the grant to Mr. Philip Serlin, the Chief Executive Officer of the Company, of (i) options to purchase <font style="color: #000000;">4,495,300 </font>Ordinary Shares (equivalent to <font style="color: #000000;">299,687 </font>ADSs) and (ii) 4,064,800 performance stock units (equivalent to <font style="color: #000000;">270,987 </font>ADSs), on such
        terms and conditions as described in Proposal 2 of the Proxy Statement.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Approval Required</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: #000000;">See &#8220;Vote Required for Approval of the Proposals&#8221; above.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Board Recommendation</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25; font-weight: bold;">Our Board of Directors recommends a vote &#8220;FOR&#8221; approval of the proposed equity grants to Mr. Serlin.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">PROPOSAL 3</div>
      <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">APPROVAL OF AMENDMENTS TO THE COMPANY&#8217;S ARTICLES OF ASSOCIATION</div>
      <div style="text-align: center; line-height: 1.25; color: #000000;">(Item 3 on the Proxy Card)</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; color: #000000; font-weight: bold;">Background</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;"><font style="color: #000000;">Our Board of Directors has approved, and recommended that the shareholders approve, an amendment to the provisions in the Company&#8217;s Articles of
          Association relating to the appointment of directors, including to establish a classified Board of Directors consisting of three classes of directors (other than the external directors) with staggered three-year terms of office (the &#8220;</font><font style="font-weight: bold; color: #000000;">Classified Board</font><font style="color: #000000;">&#8221;).&#160; The description of the proposed amendments to the Company&#8217;s Articles of Association, including the proposed </font>Classified<font style="color: #000000;"> Board, set forth below is qualified in its entirety by reference to the text of the amendment to Article 16 of the Company&#8217;s Articles of Association as set forth on <u>Appendix A</u> attached hereto (the &#8220;</font><font style="font-weight: bold; color: #000000;">Articles Amendment</font><font style="color: #000000;">&#8221;).</font></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;"><font style="color: #000000;">Our Articles of Association currently provide that all of the Company&#8217;s directors (other than external directors) are to be elected annually to
          serve until their successors have been elected and qualified.&#160; However, if the Articles Amendment is </font>approved and the Classified Board structure becomes effective<font style="color: #000000;">, our Board of Directors (other than external
          directors) would be classified into three classes, as nearly equal in number as possible, with each class having a three-year term expiring in a different year. However, for the initial terms immediately following the division of the Board of
          Directors into three classes, directors would be assigned terms of one, two or three years, as described below.</font></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;"><font style="color: #000000;">If this Proposal 3 is approved, our Board of Directors has initially designated the three classes to initially contain the following directors,
          if </font>elected<font style="color: #000000;"> at the Meeting:</font></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">Class I Directors (Term to Expire at the 2024 Annual General Meeting)</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25;">Dr. Michael Anghel</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">Class II Directors (Term to Expire at the 2025 Annual General Meeting)</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25;">Dr. B.J. Bormann</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25;">Dr. Raphael Hofstein</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">Class III Directors (Term to Expire at the 2026 Annual General Meeting)</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25;">Dr. Sandra Panem</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25;">Dr. Aharon Schwartz</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">10</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;"><font style="color: #000000;">If this Proposal 3 is approved at the Meeting and the Classified Board structure becomes effective, at each successive annual general </font>meeting<font style="color: #000000;"> of shareholders following the Meeting, the class of directors to be elected in such year would be elected for a three-year term so that the term of office of one class of directors expires in each year.&#160; If this Proposal
          3 is not approved at the Meeting, then each director (other than external directors) will continue to be elected annually, at our annual general meeting of shareholders.</font></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;"><font style="color: #000000;">The Classified Board structure also provides that a director (other than an external director) elected by the Board of Directors to fill a
          vacancy holds office until the next election of the class for which such director has been chosen, and until that director&#8217;s </font>successor<font style="color: #000000;"> has been elected and qualified or until his or her earlier death,
          resignation, retirement or removal. Any additional directorships resulting from an increase in the number of directors will be distributed between the three classes so that, as nearly as possible, each class will consist of one-third of the total
          number of directors.</font></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;"><font style="color: #000000;">To preserve the Classified Board structure and other provisions in Article 16 of our Articles of Association relating the appointment of
          directors, if approved at the Meeting, the proposed Articles Amendment provides that any amendment to the provisions of Article 16 of our Articles of Association relating to the Classified Board and certain other provisions of Article 16 relating
          to the appointment of directors, as set forth in the Articles Amendment, shall require the </font>approval<font style="color: #000000;"> of at least 65% </font>of the <font style="color: #000000;">Ordinary Shares</font> represented at a
        shareholder meeting, in person, by proxy, voting instruction form or via the ISA Electronic Voting system, voting on the matter, which we refer to as the &#8220;Special Majority Amendment Provision<font style="color: #000000;">.&#8221;</font> Under the
        Companies Law, in order to include the Special Majority Amendment Provision in our Articles of Association, such provision must be approved by the shareholders by the same special majority.&#160; Accordingly, if Proposal 3 is approved by our
        shareholders at the Meeting (by an ordinary majority) but does not receive the affirmative vote of the holders of <font style="color: #000000;">at least 65% of the Ordinary Shares&#160;</font>represented at the Meeting, in person, by proxy, voting
        instruction form or via the ISA Electronic Voting System, voting on the proposal, the <font style="color: #000000;">Articles Amendment shall be approved without the </font>Special Majority Amendment Provision.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">Further, our Articles of Association currently provide that directors shall be elected at an annual meeting and/or an extraordinary meeting and we are proposing to amend
        Article 16 of our Articles of Association to provide that directors shall be elected only at an annual meeting, as set forth on <u>Appendix A </u><font style="color: #000000;">attached hereto</font>.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; color: #000000; font-style: italic; font-weight: bold;">Advantages of Proposed Amendments to Articles of Association</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;"><font style="color: #000000;">Our Board of Directors believes that the proposed amendments to the Articles of Association will help to assure the continuity and stability of
          our long-term policies in the future and to reduce our vulnerability to hostile and potentially abusive takeover tactics </font>that<font style="color: #000000;"> could be adverse to the best interests of the Company&#8217;s shareholders.&#160; A longer
          term in office would allow our directors to stay focused on long-term value creation, without undue pressure that may come from special interest groups intent on pursuing their own agenda at the expense of the interests of the Company and its
          other shareholders.&#160; Further, it would enable us to benefit more effectively from directors&#8217; experience, knowledge of the Company and wisdom, while helping us attract and retain highly qualified individuals willing to commit the time and
          dedication necessary to understand the Company and its operations. The Classified Board would not preclude unsolicited acquisition proposals but, by eliminating the threat of imminent removal, would put our Board of Directors in a position to act
          to maximize value for all shareholders. Unless a director is removed or resigns, three annual elections are needed to replace all the directors on the classified Board of Directors. The proposed amendments to the Articles of Association may,
          therefore, discourage an individual or entity from acquiring a significant position in the Company&#8217;s shares with the intention of obtaining immediate control of the Board of Directors, without the cooperation of our Board of Directors.&#160; If this
          Proposal 3 is approved at the Meeting, these provisions will be applicable to each annual election of directors (other than external directors), including the elections following any change of control of the Company.</font></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; color: #000000; font-style: italic; font-weight: bold;">Disadvantages of Proposed Amendments to Articles of Association</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25; color: #000000;">While the proposed amendments to the Articles of Association may have the beneficial effects discussed immediately above, it may also discourage some takeover
        bids, including some that would otherwise allow shareholders the opportunity to realize a premium over the market price of their shares or that a majority of our shareholders otherwise believes may be in their best interests to accept or where the
        reason for the desired change is inadequate performance of our directors or management.&#160; Because of the additional time required to change control of our Board of Directors, the proposed amendments to the Articles of Association may make it more
        difficult and more expensive for a potential acquirer to gain control of our Board of Directors and the Company, even if the takeover bidder were to acquire a majority of our outstanding shares.&#160; Currently, a change in control of our Board of
        Directors can be made by shareholders holding a majority of the votes cast at a single annual or extraordinary meeting of shareholders where there is a contested director election.&#160; If the proposed amendments to the Articles of Association are
        amended, it will take at least two annual general meetings of shareholders following the annual meeting at which the Classified Board structure becomes effective for a potential acquirer to effect a change in control of our Board of Directors or to
        take action to remove other impediments to its acquisition of our Company, even if the potential acquirer were to acquire a majority of our outstanding Ordinary Shares.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">11</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;"><font style="color: #000000;">Further, the proposed Articles Amendments will make it more difficult for shareholders to change the majority composition of the Board of
          Directors, even if the shareholders believe such a change would be beneficial. Because the proposed </font>amendments<font style="color: #000000;"> to the Articles of Association will make the removal or replacement of directors more difficult,
          it would increase the directors&#8217; security in their positions, and could be viewed as tending to perpetuate incumbent management.</font></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;"><font style="color: #000000;">However, our Board of Directors believes that forcing potential bidders to negotiate with our Board of Directors for a change of control </font>transaction<font style="color: #000000;"> will allow our Board of Directors to better maximize shareholders value in any change of control transaction. The Board of Directors is not presently aware of any attempt, or contemplated attempt, to acquire control of
          the Company.</font></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Proposal</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">It is therefore proposed that at the Meeting the following resolution be adopted:</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: -0.55pt; margin-left: 36pt; line-height: 1.25;">&#160;&#8220;<font style="font-weight: bold;">RESOLVED, to approve certain amendments to the Company&#8217;s </font><font style="font-weight: bold; color: #000000;">Articles




          of Association</font>&#160;<font style="font-weight: bold; color: #000000;">relating to the appointment of directors of the Company, including to classify the Board of Directors into three </font><font style="font-weight: bold;">classes</font><font style="font-weight: bold; color: #000000;"> with staggered three-year terms, as set forth on <u>Appendix A</u>.</font><font style="color: #000000;">&#8221;</font></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; color: #000000; font-weight: bold;">Approval Required</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25; color: #000000;">See &#8220;Vote Required for Approval of the Proposals&#8221; above.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; color: #000000; font-weight: bold;">Board Recommendation</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25; font-weight: bold;"><font style="color: #000000;">Our Board </font>of<font style="color: #000000;"> Directors recommends a vote &#8220;FOR&#8221; approval of the proposed amendments to
          the Articles of Association.</font></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">PROPOSAL 4</div>
      <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">RE-APPOINTMENT OF INDEPENDENT PUBLIC AUDITOR</div>
      <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">AND AUTHORIZATION OF THE AUDIT COMMITTEE TO FIX THEIR REMUNERATION</div>
      <div style="text-align: center; line-height: 1.25; color: #000000;">(Item 4 on the Proxy Card)</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; color: #000000; font-weight: bold;">Background</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="color: #000000;">Kesselman &amp; Kesselman, a member firm of PricewaterhouseCoopers International Limited, have audited the Company&#8217;s financial statements beginning
          with the financial statements for the year ended December 31, 2023. Except as the Company&#8217;s auditors, </font>and, from time to time and to a limited extent, as tax consultants and providers of some audit-related and other services,<font style="color: #000000;"> there is no other affiliation between such firm and the Company.</font></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="color: #000000;">The Companies Law requires shareholder approval of the appointment of the Company&#8217;s independent public accountants for the fiscal year ending
          December 31, 2023. Our Board of Directors recommended, pursuant to the recommendation of our Audit Committee, the re-appointment of the accounting firm of Kesselman &amp; Kesselman as our independent registered public accounting firm to perform
          the audit of our consolidated financial statements for the fiscal year ending December 31, 2023 </font>and for such additional period until the next annual general meeting<font style="color: #000000;">. The Board of Directors believes that the
          appointment of Kesselman &amp; Kesselman as the Company&#8217;s independent registered public accounting firm to perform the audit of the Company&#8217;s consolidated financial statements for the fiscal year ending December 31, 2023, is appropriate and in
          the interests of the Company and its shareholders. Subject to the approval of this proposal, the Audit Committee of the Board of Directors will fix the compensation of Kesselman &amp; Kesselman in accordance with the scope and nature of its
          services to the Company.</font></div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">12</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: #000000;">The following table sets forth, for each of the years indicated, the fees billed by Kesselman &amp; Kesselman, a member firm of PricewaterhouseCoopers
          International Ltd., our independent registered public accounting firm.</div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" class="cfttable" id="z6cd7a0661f694e24918ca463216ef76a" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">

          <tr>
            <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">
              <div style="line-height: 1.25; color: #000000;">&#160;</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">Year Ended December 31,</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">
              <div style="line-height: 1.25; color: #000000;">&#160;</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;"> 2021</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">2022</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom;">
              <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">Services Rendered</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" colspan="6" style="vertical-align: bottom;">
              <div style="text-align: center; line-height: 1.25; color: #000000; font-style: italic;">(in thousands of U.S. dollars)</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top;">
              <div style="line-height: 1.25; color: #000000;">&#160;</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: top;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom;">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: top;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; background-color: #CCEEFF; width: 76%;">
              <div style="line-height: 1.25; color: #000000;">Audit Fees<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25; color: #000000;">130</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25; color: #000000;">130</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; width: 76%;">
              <div style="line-height: 1.25; color: #000000;">Audit-Related Fees<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25; color: #000000;">25</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25; color: #000000;">4</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; background-color: #CCEEFF; width: 76%;">
              <div style="line-height: 1.25; color: #000000;">Tax Fees<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup></div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25; color: #000000;">20</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25; color: #000000;">18</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
              <div style="line-height: 1.25; color: #000000;">All Other Fees</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25; color: #000000;">-</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25; color: #000000;">-</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; background-color: #CCEEFF; width: 76%;">
              <div style="line-height: 1.25; color: #000000;">Total</div>
            </td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25; color: #000000;">175</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" class="cftcurrcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" class="cftnumcell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25; color: #000000;">152</div>
            </td>
            <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
          </tr>

      </table>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25; color: #000000;">&#160;</div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z1c78834a962545e6a17b18b845595187">

          <tr>
            <td style="width: 2.98%; vertical-align: top;">
              <div style="line-height: 1.25; color: #000000;">(1)</div>
            </td>
            <td style="width: 97.02%; vertical-align: top;">
              <div style="line-height: 1.25; color: #000000;">Audit fees consist of services that would normally be provided in connection with statutory and regulatory filings or engagements, including services that generally only the independent
                accountant can reasonably provide.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 2.98%; vertical-align: top;">
              <div style="line-height: 1.25; color: #000000;">&#160;</div>
            </td>
            <td style="width: 97.02%; vertical-align: top;">
              <div style="line-height: 1.25; color: #000000;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 2.98%; vertical-align: top;">
              <div style="line-height: 1.25; color: #000000;">(2)</div>
            </td>
            <td style="width: 97.02%; vertical-align: top;">
              <div style="line-height: 1.25; color: #000000;">Audit-related services relate to reports to the Israel Innovation Authority and work regarding a public listing or offering.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 2.98%; vertical-align: top;">
              <div style="line-height: 1.25; color: #000000;">&#160;</div>
            </td>
            <td style="width: 97.02%; vertical-align: top;">
              <div style="line-height: 1.25; color: #000000;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 2.98%; vertical-align: top;">
              <div style="line-height: 1.25; color: #000000;">(3)</div>
            </td>
            <td style="width: 97.02%; vertical-align: top;">
              <div style="line-height: 1.25; color: #000000;">Tax fees relate to tax compliance, planning and advice.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25; color: #000000;">&#160;</div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Proposal</div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">It is therefore proposed that at the Meeting the following resolution be adopted:</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-right: 36pt; margin-left: 36pt; line-height: 1.25; color: #000000; font-weight: bold;">&#8220;RESOLVED, to reappoint Kesselman &amp; Kesselman, Certified Public Accountants (Isr.), a member firm of
        PricewaterhouseCoopers International Limited, as the independent registered public accounting firm of the Company for the year ending December 31, 2023 and for such additional period until the next annual general meeting, and to authorize the Audit
        Committee of the Board of Directors to fix the compensation of said auditors in accordance with the scope and nature of their services.&#8221;</div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25; color: #000000;">&#160;</div>
      </div>
      <div style="text-align: justify; line-height: 1.25; color: #000000; font-weight: bold;">Approval Required</div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: #000000;">See &#8220;Vote Required for Approval of the Proposals&#8221; above. &#160;</div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="text-align: justify; line-height: 1.25; color: #000000; font-weight: bold;">Board Recommendation</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: #000000; font-weight: bold;">Our Board of Directors recommends a vote &#8220;FOR&#8221; approval of the re-appointment of Kesselman &amp; Kesselman as the independent public auditors
        of the Company for the year ending December 31, 2023 and for such additional period until the next annual general meeting, and the authorization of the Audit Committee of the Board of Directors to fix their compensation.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; margin-right: 4.2pt; line-height: 1.25; color: #000000; font-weight: bold;">REVIEW OF THE COMPANY&#8217;S AUDITED FINANCIAL STATEMENTS FOR THE</div>
      <div style="text-align: center; margin-right: 4.2pt; line-height: 1.25; color: #000000; font-weight: bold;">YEAR ENDED DECEMBER 31, 2022</div>
      <div style="text-align: justify; line-height: 1.25; color: #000000;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="color: #000000;">The audited financial statements of the Company for the fiscal year ended December 31, 2022 were filed together with the Company&#8217;s Annual Report on
          Form 20-F, which was filed on March 22, 2023 with the SEC and is available at the SEC&#8217;s website, </font><font style="color: #0563C1;"><u>www.sec.gov</u></font><font style="color: #000000;">, and at the Magna website of the ISA at </font><font style="color: #0563C1;"><u>www.magna.isa.gov.il</u></font>. <font style="color: #000000;"> We will hold a discussion with respect to the financial statements at the Meeting. This item will not involve a vote by the shareholders. </font>None of
        the audited financial statements, the Form 20-F nor the contents of our website form part of the proxy solicitation material.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">OTHER BUSINESS</div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="color: #000000;">The Company&#8217;s management is not aware of any other business to be transacted at the Meeting.&#160; However, if any other matters are properly presented
          to the Meeting, the persons named as </font><font style="color: #252525;">proxies</font><font style="color: #000000;"> in the enclosed form of </font><font style="color: #252525;">proxy</font><font style="color: #000000;"> will vote upon such
          matters in accordance with their best judgment.</font></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">13</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; text-indent: 36pt; line-height: 1.25; color: #000000; font-weight: bold;">ADDITIONAL INFORMATION</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="color: #000000;">We are subject to the information reporting requirements of the U.S. Securities Exchange Act of 1934, as amended (the &#8220;</font><font style="font-weight: bold; color: #000000;">Exchange Act</font><font style="color: #000000;">&#8221;), as applicable to foreign private issuers, and we fulfill the obligations with respect to those requirements by filing reports with the SEC. Our SEC
          filings are available to the public on the SEC&#8217;s website at </font><font style="color: #0563C1;"><u>www.sec.gov</u></font><font style="color: #000000;">, the ISA&#8217;s website at </font><font style="color: #0563C1;"><u>www.magna.isa.gov.il</u></font><font style="color: #000000;"> and the Company&#8217;s website at </font><font style="color: #0563C1;"><u>www.biolinerx.com</u></font><font style="color: #000000;">. Shareholders may obtain information directly from the Company, whose registered office is
          at 2 HaMa&#8217;ayan Street, Modi&#8217;in 7177871, Israel and whose telephone number is +972-8-642-9100.&#160; </font>The contents of our website do not form part of the proxy solicitation material.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="color: #000000;">As a foreign private issuer, we are exempt from the rules under the Exchange Act related to the furnishing and content of </font><font style="color: #252525;">proxy</font><font style="color: #000000;"> statements. The circulation of this </font><font style="color: #252525;">proxy</font><font style="color: #000000;"> statement and related notice should not be taken as an
          admission that we are subject to those </font><font style="color: #252525;">proxy</font><font style="color: #000000;"> rules. Furthermore, our officers, directors and principal shareholders are exempt from the reporting and &#8220;short-swing&#8221; profit
          recovery provisions contained in Section 16 of the Exchange Act and the rules thereunder, with respect to their purchases and sales of securities.&#160; Lastly, we are not required under the Exchange Act to file periodic reports and financial
          statements with the SEC as frequently or as promptly as United States companies whose securities are registered under the Exchange Act.</font></div>
      <div style="text-align: justify; line-height: 1.25; color: #000000;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="color: #000000;">YOU SHOULD RELY ONLY ON THE INFORMATION CONTAINED IN THIS </font><font style="color: #252525;">PROXY</font><font style="color: #000000;"> STATEMENT
          OR THE INFORMATION FURNISHED TO YOU IN CONNECTION WITH THIS </font><font style="color: #252525;">PROXY</font><font style="color: #000000;"> STATEMENT WHEN VOTING ON THE MATTERS SUBMITTED TO SHAREHOLDER APPROVAL HEREUNDER. WE HAVE NOT AUTHORIZED
          ANYONE TO PROVIDE YOU WITH INFORMATION THAT IS DIFFERENT FROM WHAT IS CONTAINED IN THIS DOCUMENT. THIS </font><font style="color: #252525;">PROXY</font><font style="color: #000000;"> STATEMENT IS DATED JUNE 23, 2023. YOU SHOULD NOT ASSUME THAT
          THE INFORMATION CONTAINED IN THIS DOCUMENT IS ACCURATE AS OF ANY DATE OTHER THAN JUNE 23, 2023, AND THE MAILING OF THIS DOCUMENT TO SHAREHOLDERS SHOULD NOT CREATE ANY IMPLICATION TO THE CONTRARY.</font></div>
      <div style="text-align: justify; line-height: 1.25; color: #000000;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; color: #000000;">
        <table cellspacing="0" cellpadding="0" border="0" id="z042783fd577d4899a6a78bd4e0d0d3db" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

            <tr>
              <td style="width: 50.00%;">
                <div>&#160;</div>
              </td>
              <td style="width: 50.00%;">
                <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">By Order of the Board of Directors</div>
                <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                </div>
                <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">Dr. Aharon Schwartz<br>
                  Chairman of the Board of Directors</div>
              </td>
            </tr>

        </table>
      </div>
      <br>
      <div style="text-align: justify; line-height: 1.25; color: #000000;">June 23, 2023</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">14</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <!--PROfilePageNumberReset%Num%1%A - %%-->
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; color: #000000;"><u>Appendix A</u></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25">
        <div style="line-height: 1.25">
          <div style="line-height: 1.25">
            <div>
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', serif; font-weight: bold;"><u>AOA Amendment</u></div>
              <div style="line-height: 1.25">&#160;</div>
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', serif; font-weight: bold;">Appointment of the Board of Directors and Cessation of Office Thereof</div>
              <div style="line-height: 1.25">&#160;</div>
              <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zfa7839e17e094d16a6d44d2fe4c498ed">

                  <tr>
                    <td style="width: 28.35pt; vertical-align: top; font-family: 'Times New Roman', serif;">16.1</td>
                    <td style="width: auto; vertical-align: top; text-align: justify;">
                      <div style="font-family: 'Times New Roman', serif;">The number of directors in the Company shall be determined from time to time by the annual general meeting, provided that this shall not be fewer than 5 and not more than 10
                        directors, including external directors (if any were elected). The number of external directors in the Company shall not be less than the number determined in the Companies Law.</div>
                    </td>
                  </tr>

              </table>
              <div style="line-height: 1.25">&#160;
                <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                    <tr>
                      <td style="width: 28.35pt; vertical-align: top;">16.2<br>
                      </td>
                      <td style="width: 28.35pt; vertical-align: top; font-family: 'Times New Roman',serif;">(a)<br>
                      </td>
                      <td style="vertical-align: top; text-align: justify; width: auto;">
                        <div style="font-family: 'Times New Roman', serif;">
                          <div> Directors shall be elected at the annual general meeting by vote of a shareholders&#8217; resolution. The directors, excluding the external directors (if any were elected), shall be
                            classified, with respect to the term for which they each severally hold office, into three classes, as nearly equal in number as practicable, hereby designated as Class&#160;I, Class&#160;II and Class&#160;III.</div>
                        </div>
                      </td>
                    </tr>

                </table>
                <div style="line-height: 1.25">&#160;</div>
              </div>
              <div style="text-align: justify; text-indent: -35.45pt; margin-left: 92.15pt; line-height: 1.25; font-family: 'Times New Roman', serif;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The term of office of the initial Class&#160;I directors shall expire when their successors are
                elected and qualified at the first annual general meeting to be held following the approval of this provision;</div>
              <div style="line-height: 1.25">&#160;</div>
              <div style="text-align: justify; text-indent: -35.45pt; margin-left: 92.15pt; line-height: 1.25; font-family: 'Times New Roman', serif;">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The term of office of the initial Class&#160;II directors shall expire when their successors are
                elected and qualified at the first annual general meeting following the annual general meeting referred to in clause (i)&#160;above; and</div>
              <div style="line-height: 1.25">&#160;</div>
              <div style="text-align: justify; text-indent: -35.45pt; margin-left: 92.15pt; line-height: 1.25; font-family: 'Times New Roman', serif;">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The term of office of the initial Class&#160;III directors shall expire when their successors are
                elected and qualified at the first annual general meeting following the annual general meeting referred to in clause (ii)&#160;above.</div>
              <div style="line-height: 1.25">&#160;</div>
              <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z01ea8410860e437a83f52e2e124a84d0">

                  <tr>
                    <td style="width: 28.35pt;"><br>
                    </td>
                    <td style="width: 28.35pt; vertical-align: top; font-family: 'Times New Roman', serif;">(b)</td>
                    <td style="width: auto; vertical-align: top; text-align: justify;">
                      <div style="font-family: 'Times New Roman', serif;">At each annual general meeting, commencing with the annual general meeting to be held following the approval of this provision (anticipated to be in 2024), each of the successors
                        elected to replace the directors of a Class&#160;whose term shall have expired at such annual general meeting shall be elected to hold office until the third annual general meeting next succeeding his or her election (or re-election) and
                        until his or her respective successor shall have been elected and qualified. Notwithstanding anything to the contrary, each director shall serve subject to section 16 hereof until his or her successor is elected and qualified or
                        until such earlier time as such director&#8217;s office is vacated, or his earlier removal pursuant to this section 16.</div>
                    </td>
                  </tr>

              </table>
              <div style="line-height: 1.25">&#160;</div>
              <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb3872fb9c82c4002af1ae64d4d8ea04b">

                  <tr>
                    <td style="width: 28.35pt;"><br>
                    </td>
                    <td style="width: 28.35pt; vertical-align: top; font-family: 'Times New Roman', serif;">(c)</td>
                    <td style="width: auto; vertical-align: top; text-align: justify;">
                      <div style="font-family: 'Times New Roman', serif;">If the number of directors (excluding external directors, if any were elected) that comprise the Board of Directors is hereafter changed, any newly created directorships or decrease
                        in directorships shall be so apportioned by the Board of Directors among the classes as to make all classes as nearly equal in number as is practicable, provided that no decrease in the number of directors constituting the Board of
                        Directors shall shorten the term of any incumbent director.</div>
                    </td>
                  </tr>

              </table>
              <div style="line-height: 1.25">&#160;</div>
              <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z307c55436d57447f89b0c879b911b962">

                  <tr>
                    <td style="width: 28.35pt; vertical-align: top; font-family: 'Times New Roman', serif;">16.3</td>
                    <td style="width: auto; vertical-align: top; text-align: justify;">
                      <div style="font-family: 'Times New Roman', serif;">In addition to the content of section 16.2 above, the Board of Directors is entitled to appoint a director in place of a director whose position has become vacant and/or by way of an
                        addition to the Board of Directors, subject to the maximum number of directors on the Board of Directors as stated in section 16.1 above. The appointment of a director by the Board of Directors <font style="color: #000000;">to fill
                          any vacancy shall only be for the remaining period of time during which the director whose service has ended would have held office, or in case of a vacancy due to the number of directors serving being less than the maximum number
                          stated in </font>section 16.1 above<font style="color: #000000;">, the Board of Directors shall determine at the time of appointment the class, pursuant to </font>section 16.2,<font style="color: #000000;"> to which the
                          additional director is assigned</font>.</div>
                    </td>
                  </tr>

              </table>
              <div style="line-height: 1.25">&#160;</div>
              <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc9da0422776b4a6a9183ab52616b0fbe">

                  <tr>
                    <td style="width: 28.35pt; vertical-align: top; font-family: 'Times New Roman', serif;">16.4</td>
                    <td style="width: auto; vertical-align: top; text-align: justify;">
                      <div style="font-family: 'Times New Roman', serif;">A director whose period of office has expired may be reelected, with the exception of an external director, who may be reelected for an additional period of office subject to the
                        provisions of the law.</div>
                    </td>
                  </tr>

              </table>
              <div style="line-height: 1.25">&#160;</div>
              <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">A - 1</font></div>
                <div class="BRPFPageBreak" style="page-break-after: always;">
                  <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
              </div>
              <div> <br>
              </div>
              <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z20c31e5446424f49ad32aac42afa5758">

                  <tr>
                    <td style="width: 28.35pt; vertical-align: top; font-family: 'Times New Roman', serif;">16.5</td>
                    <td style="width: auto; vertical-align: top; text-align: justify;">
                      <div style="font-family: 'Times New Roman', serif;">The office of a director shall commence on the date of his/her appointment by the annual meeting and/or&#160; the Board of Directors, or on a later date if this date is determined in the
                        decision of appointment at the annual meeting and/or by the Board of Directors.</div>
                    </td>
                  </tr>

              </table>
              <div style="line-height: 1.25">&#160;</div>
              <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z11f0fb7c9e054356acbf707a080ff417">

                  <tr>
                    <td style="width: 28.35pt; vertical-align: top; font-family: 'Times New Roman', serif;">16.6</td>
                    <td style="width: auto; vertical-align: top; text-align: justify;">
                      <div style="font-family: 'Times New Roman', serif;">The Board of Directors shall elect one of its members as the chairperson of the Board of Directors. The elected chairperson shall run the meetings of the Board of Directors and shall
                        sign the minutes of the discussion. If no chairperson is elected, or if the chairperson of the Board of Directors is not present after 15 minutes from the time set for the meeting, the directors present shall choose one of their
                        number to serve as the chairperson at that meeting, and the chosen member shall run the meeting and sign the minutes of the discussion.</div>
                    </td>
                  </tr>

              </table>
              <div style="line-height: 1.25">&#160;</div>
              <div style="text-align: justify; margin-left: 28.35pt; line-height: 1.25; font-family: 'Times New Roman', serif;">The chairperson of the Board of Directors shall not be the general director of the Company unless the conditions stipulated in
                Article 121(C) of the Companies Law apply.</div>
              <div style="line-height: 1.25">&#160;</div>
              <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z74bf8ee98e3b47e280ff7cf3385e2a19">

                  <tr>
                    <td style="width: 28.35pt; vertical-align: top; font-family: 'Times New Roman', serif;">16.7</td>
                    <td style="width: auto; vertical-align: top; text-align: justify;">
                      <div style="font-family: 'Times New Roman', serif;">The general meeting is entitled to remove any director from their office prior to the end of the period of their office, inter alia whether the director was appointed thereby in
                        accordance with section 16.2 above or was appointed by the Board of Directors in accordance with section 16.3 above, provided that the director shall be given a reasonable opportunity to state their case before the general meeting.</div>
                    </td>
                  </tr>

              </table>
              <div style="line-height: 1.25">&#160;</div>
              <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd3d216f535ec4e01b0f1ab9043042b84">

                  <tr>
                    <td style="width: 28.35pt; vertical-align: top; font-family: 'Times New Roman', serif;">16.8</td>
                    <td style="width: auto; vertical-align: top; text-align: justify;">
                      <div style="font-family: 'Times New Roman', serif;">Any director is entitled, with the agreement of the Board of Directors, to appoint a substitute for themselves (hereinafter &#8211;a &#8220;Substitute Director&#8221;), provided that a person who is
                        not competent shall not be appointed to serve as a Substitute Director, nor a person who has been appointed as a Substitute Director for another director and/or a person who is already serving as a director in the Company.</div>
                    </td>
                  </tr>

              </table>
              <div style="line-height: 1.25">&#160;</div>
              <div style="text-align: justify; margin-left: 28.35pt; line-height: 1.25; font-family: 'Times New Roman', serif;">The appointment or cessation of office of a Substitute Director shall be made in a written document signed by the director who
                appointed him; in any case, however, the office of a Substitute Director shall be terminated if one of the cases stipulated in the paragraphs in section 16.9 below shall apply, or if the office of the member of the Board of Directors for
                whom he serves as a substitute shall become vacant for any reason.</div>
              <div style="line-height: 1.25">&#160;</div>
              <div style="text-align: justify; margin-left: 28.35pt; line-height: 1.25; font-family: 'Times New Roman', serif;">A Substitute Director is considered tantamount to a director and all the legal provisions and the provisions of these Articles
                shall apply, with the exception of the provisions regarding the appointment and/or dismissal of a director as established in these Articles.</div>
              <div style="line-height: 1.25">&#160;</div>
              <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z24822ee97ed2427bbeabbdbcc333ca09">

                  <tr>
                    <td style="width: 28.35pt; vertical-align: top; font-family: 'Times New Roman', serif;">16.9</td>
                    <td style="width: auto; vertical-align: top; text-align: justify;">
                      <div style="font-family: 'Times New Roman', serif;">The office of a director shall become vacant in any of the following cases:</div>
                    </td>
                  </tr>

              </table>
              <div style="line-height: 1.25">&#160;</div>
              <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zab381c5206d04663be04915a0df5f88e">

                  <tr>
                    <td style="width: 28.35pt;"><br>
                    </td>
                    <td style="width: 79.65pt; vertical-align: top; font-family: 'Times New Roman', serif;">16.9.1</td>
                    <td style="width: auto; vertical-align: top; text-align: justify;">
                      <div style="font-family: 'Times New Roman', serif;">The director resigns from office by means of a letter signed, submitted to the Company and detailing the reasons for the resignation;</div>
                    </td>
                  </tr>

              </table>
              <div style="line-height: 1.25">&#160;</div>
              <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd280d9ae9c7a4a52b7989f012db9796f">

                  <tr>
                    <td style="width: 28.35pt;"><br>
                    </td>
                    <td style="width: 79.65pt; vertical-align: top; font-family: 'Times New Roman', serif;">16.9.2</td>
                    <td style="width: auto; vertical-align: top; text-align: justify;">
                      <div style="font-family: 'Times New Roman', serif;">The director is removed from office by the general meeting;</div>
                    </td>
                  </tr>

              </table>
              <div style="line-height: 1.25">&#160;</div>
              <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za9a34fd0f1b14af2818cb1b17f0b4be2">

                  <tr>
                    <td style="width: 28.35pt;"><br>
                    </td>
                    <td style="width: 79.65pt; vertical-align: top; font-family: 'Times New Roman', serif;">16.9.3</td>
                    <td style="width: auto; vertical-align: top; text-align: justify;">
                      <div style="font-family: 'Times New Roman', serif;">The director is convicted of an offense as stated in Article 232 of the Companies Law;</div>
                    </td>
                  </tr>

              </table>
              <div style="line-height: 1.25">&#160;</div>
              <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8084f438c5f54c589c3a0bae54dbddcf">

                  <tr>
                    <td style="width: 28.35pt;"><br>
                    </td>
                    <td style="width: 79.65pt; vertical-align: top; font-family: 'Times New Roman', serif;">16.9.4</td>
                    <td style="width: auto; vertical-align: top; text-align: justify;">
                      <div style="font-family: 'Times New Roman', serif;">In accordance with a court decision as stated in Article 233 of the Companies Law;</div>
                    </td>
                  </tr>

              </table>
              <div style="line-height: 1.25">&#160;</div>
              <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z00034efd6a894f62821f03688e758436">

                  <tr>
                    <td style="width: 28.35pt;"><br>
                    </td>
                    <td style="width: 79.65pt; vertical-align: top; font-family: 'Times New Roman', serif;">16.9.5</td>
                    <td style="width: auto; vertical-align: top; text-align: justify;">
                      <div style="font-family: 'Times New Roman', serif;">The director is declared legally incompetent; or died</div>
                    </td>
                  </tr>

              </table>
              <div style="line-height: 1.25">&#160;</div>
              <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc889ed5e640f42da93b45b31f7418e20">

                  <tr>
                    <td style="width: 28.35pt;"><br>
                    </td>
                    <td style="width: 79.65pt; vertical-align: top; font-family: 'Times New Roman', serif;">16.9.6</td>
                    <td style="width: auto; vertical-align: top; text-align: justify;">
                      <div style="font-family: 'Times New Roman', serif;">The director is declared bankrupt and, if the director is a corporation &#8211; it opted for voluntary liquidation or a liquidation order was issued against it.</div>
                    </td>
                  </tr>

              </table>
              <div style="line-height: 1.25">&#160;</div>
              <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8d238429a2c64c73a47f66d8f808c834">

                  <tr>
                    <td style="width: 42.55pt; vertical-align: top; font-family: 'Times New Roman', serif;">16.10</td>
                    <td style="width: auto; vertical-align: top; text-align: justify;">
                      <div style="font-family: 'Times New Roman', serif;">In the event that the position of a director becomes vacant, the remaining directors shall be entitled to continue to act, provided the number of directors remaining shall not be
                        less than the minimum number of directors as stated above in section 16.1 above. If the number of directors falls below the above-mentioned minimum number, the remaining directors shall be entitled to act solely in order to fill the
                        place of the director that has become vacant as stated in section 16.3 above, or in order to convene a general meeting of the Company, and pending the convening of the general meeting of the Company as stated they may act to manage
                        the Company&#8217;s affairs solely in matters that cannot be delayed.</div>
                    </td>
                  </tr>

              </table>
              <div style="line-height: 1.25">&#160;</div>
              <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5d50e1e8efaa4e7ab89edccadf6ef110">

                  <tr>
                    <td style="width: 42.55pt; vertical-align: top; font-family: 'Times New Roman', serif;">16.11</td>
                    <td style="width: auto; vertical-align: top; text-align: justify;">
                      <div style="font-family: 'Times New Roman', serif;">The terms and conditions of the office of the members of the Board of Directors shall be authorized in accordance with the provisions of the Companies Law.</div>
                    </td>
                  </tr>

              </table>
              <div style="line-height: 1.25">&#160;</div>
              <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze9344c152d5f430ebde95b7237ae90c9">

                  <tr>
                    <td style="width: 42.55pt; vertical-align: top; font-family: 'Times New Roman', serif;">16. 12</td>
                    <td style="width: auto; vertical-align: top; text-align: justify;">
                      <div style="font-family: 'Times New Roman', serif;">Notwithstanding anything to the contrary herein, clauses 16.1, 16.2 and 16.3 above may only be amended, replaced or suspended by a resolution adopted at an annual general meeting by
                        a majority of at least 65% of the ordinary shares represented at such meeting (in person, by proxy, by voting instruction form or via the electronic voting system of the Israel Securities Authority) voting on the proposal.</div>
                    </td>
                  </tr>

              </table>
              <div style="line-height: 1.25">&#160;</div>
              <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc0901b6baaf64689b2b8ee1e9f8128f6">

                  <tr>
                    <td style="width: 42.55pt; vertical-align: top; font-family: 'Times New Roman', serif;">16. 13</td>
                    <td style="width: auto; vertical-align: top; text-align: justify;">
                      <div style="font-family: 'Times New Roman', serif;">Notwithstanding anything to the contrary in these Articles, the election, qualification, removal or dismissal of external directors, if so elected, shall be only in accordance with
                        the applicable provisions set forth in the Companies Law.</div>
                    </td>
                  </tr>

              </table>
              <div style="line-height: 1.25">&#160;</div>
            </div>
          </div>
          <div style="line-height: 1.25; text-align: center;"><font style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;" class="BRPFPageNumber">A - 2</font></div>
        </div>
      </div>
    </div>
  </div>
  <div style="text-align: center;" class="BRPFPageNumberArea">
    <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>3
<FILENAME>exhibit_2.htm
<DESCRIPTION>PROXY CARD
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using Broadridge PROfile 23.5.1.5152
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div style="text-align: right;"><u><font style="font-weight: bold;">Exhibit 2</font></u><br>
    </div>
    <div><u><font style="font-weight: bold;"> </font></u><br>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zcc29ee2562b7471d923e9d902fd6578c">

          <tr>
            <td colspan="3" style="width: 100%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">BIOLINERX LTD.</div>
              <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
              </div>
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">For the <font style="color: #000000;">Annual</font> General Meeting of Shareholders<br>
                to be held on August 7, 2023</div>
              <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
              </div>
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS</div>
              <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
              </div>
            </td>
          </tr>
          <tr>
            <td colspan="3" style="width: 100%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25;">The undersigned shareholder of BioLineRx Ltd. (the &#8220;<font style="font-weight: bold;">Company</font>&#8221;) hereby appoints Mali Zeevi and/or Raziel Fried, and each or either of them, the true
                and lawful attorney, agent and proxy of the undersigned, with full power of substitution, to vote, as designated below, all of the ordinary shares of the Company which the undersigned is entitled in any capacity to vote at the <font style="color: #000000;">Annual</font> General Meeting of the shareholders of the Company which will be held at the offices of the Company at Modi&#8217;in Technology Park, 2 HaMa&#8217;ayan Street, Modi&#8217;in 7177871, Israel, on August 7, 2023 at 3:00
                p.m. (Israel time), and all adjournments and postponements thereof.</div>
              <div style="text-align: justify; line-height: 1.25;"> <br>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.2%; vertical-align: middle; border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25;">(CONTINUED AND TO BE SIGNED ON REVERSE SIDE)</div>
            </td>
            <td style="width: 26.24%; vertical-align: middle; border-bottom: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-variant: small-caps;">See<br>
                Reverse<br>
                Side</div>
            </td>
            <td style="width: 24.56%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">&#160;</td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">ANNUAL GENERAL MEETING OF SHAREHOLDERS OF</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">BIOLINERX LTD.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">August 7, 2023</div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z5e8720b60c1c4b468647894c83237736">

          <tr>
            <td colspan="6" style="width: 100%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
              </div>
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">THIS PROXY WHEN PROPERLY EXECUTED WILL BE VOTED AS DIRECTED HEREIN.<br>
              </div>
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">IF NO DIRECTION IS INDICATED, THIS PROXY WILL BE VOTED &#8220;FOR&#8221; THE ELECTION OF THE DIRECTORS </div>
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">NAMED IN ITEM 1 AND &#8220;FOR&#8221; ALL OTHER PROPOSALS.</div>
              <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
              </div>
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">VOTES CAST FOR ITEM 2 WILL NOT BE COUNTED UNLESS &#8220;YES&#8221; OR &#8220;NO&#8221; HAS BEEN SPECIFIED AS TO </div>
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">WHETHER THE SHAREHOLDER HAS A PERSONAL INTEREST (AS DEFINED IN THE PROXY STATEMENT) WITH </div>
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">RESPECT TO SUCH PROPOSAL</div>
              <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 3.76%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td colspan="4" style="width: 64.27%; vertical-align: middle; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25;"><font style="font-weight: bold;">Please mark your vote for the following resolutions as in this example </font><font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</font></div>
              <div style="text-align: justify; line-height: 1.25;"><font style="font-family: 'Segoe UI Symbol', sans-serif;"> <br>
                </font></div>
            </td>
            <td style="width: 31.96%; vertical-align: middle; border-bottom: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">&#160;</td>
          </tr>
          <tr>
            <td style="width: 3.76%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25;">1.</div>
            </td>
            <td style="width: 36.34%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">TO APPROVE the re-election of the following persons to the Board of Directors, each to serve until the next annual general meeting of shareholders and until their respective successors are
                duly elected and qualified, or each to serve for staggered terms ending at the 2024, 2025 and 2026 annual general meetings of shareholders, if Proposal 3 is approved:</div>
              <div style="text-align: justify; line-height: 1.25;"> <br>
              </div>
            </td>
            <td style="width: 8.16%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">FOR</div>
            </td>
            <td style="width: 9.88%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">AGAINST</div>
              <br>
            </td>
            <td style="width: 9.9%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">ABSTAIN</div>
              <br>
            </td>
            <td rowspan="11" style="width: 31.96%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">&#160;</td>
          </tr>
          <tr>
            <td style="width: 3.76%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 36.34%; vertical-align: top;">Aharon Schwartz</td>
            <td style="width: 8.16%; vertical-align: top; text-align: center;">&#9744;</td>
            <td style="width: 9.88%; vertical-align: top; text-align: center;">&#9744;</td>
            <td style="width: 9.9%; vertical-align: top; text-align: center;">&#9744;</td>
          </tr>
          <tr>
            <td style="width: 3.76%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 36.34%; vertical-align: top;">&#160;</td>
            <td style="width: 8.16%; vertical-align: top; text-align: center;">&#160;</td>
            <td style="width: 9.88%; vertical-align: top; text-align: center;">&#160;</td>
            <td style="width: 9.9%; vertical-align: top; text-align: center;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 3.76%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 36.34%; vertical-align: top;">Michael Anghel</td>
            <td style="width: 8.16%; vertical-align: top; text-align: center;">&#9744;</td>
            <td style="width: 9.88%; vertical-align: top; text-align: center;">&#9744;</td>
            <td style="width: 9.9%; vertical-align: top; text-align: center;">&#9744;</td>
          </tr>
          <tr>
            <td style="width: 3.76%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 36.34%; vertical-align: top;">&#160;</td>
            <td style="width: 8.16%; vertical-align: top; text-align: center;">&#160;</td>
            <td style="width: 9.88%; vertical-align: top; text-align: center;">&#160;</td>
            <td style="width: 9.9%; vertical-align: top; text-align: center;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 3.76%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 36.34%; vertical-align: top;">B.J. Bormann</td>
            <td style="width: 8.16%; vertical-align: top; text-align: center;">&#9744;</td>
            <td style="width: 9.88%; vertical-align: top; text-align: center;">&#9744;</td>
            <td style="width: 9.9%; vertical-align: top; text-align: center;">&#9744;</td>
          </tr>
          <tr>
            <td style="width: 3.76%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 36.34%; vertical-align: top;">&#160;</td>
            <td style="width: 8.16%; vertical-align: top; text-align: center;">&#160;</td>
            <td style="width: 9.88%; vertical-align: top; text-align: center;">&#160;</td>
            <td style="width: 9.9%; vertical-align: top; text-align: center;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 3.76%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 36.34%; vertical-align: top;">Raphael Hofstein <br>
            </td>
            <td style="width: 8.16%; vertical-align: top; text-align: center;">&#9744;</td>
            <td style="width: 9.88%; vertical-align: top; text-align: center;">&#9744;</td>
            <td style="width: 9.9%; vertical-align: top; text-align: center;">&#9744;</td>
          </tr>
          <tr>
            <td style="width: 3.76%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 36.34%; vertical-align: top;">&#160;</td>
            <td style="width: 8.16%; vertical-align: top; text-align: center;">&#160;</td>
            <td style="width: 9.88%; vertical-align: top; text-align: center;">&#160;</td>
            <td style="width: 9.9%; vertical-align: top; text-align: center;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 3.76%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 36.34%; vertical-align: top;">Sandra Panem <br>
            </td>
            <td style="width: 8.16%; vertical-align: top; text-align: center;">&#9744; <br>
            </td>
            <td style="width: 9.88%; vertical-align: top; text-align: center;">&#9744;</td>
            <td style="width: 9.9%; vertical-align: top; text-align: center;">&#9744;</td>
          </tr>
          <tr>
            <td style="width: 3.76%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 36.34%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 8.16%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);"><br>
            </td>
            <td style="width: 9.88%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 9.9%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          </tr>
          <tr>
            <td colspan="1" rowspan="2" style="width: 3.76%; vertical-align: top; text-align: center; border-left: 2px solid rgb(0, 0, 0);">2. <br>
            </td>
            <td colspan="1" rowspan="2" style="width: 36.34%; vertical-align: top;">
              <div style="text-align: justify;">TO APPROVE the grant of equity compensation to Philip Serlin, the Company&#8217;s Chief Executive Officer, as described in Proposal 2 of the Proxy Statement.<br>
              </div>
            </td>
            <td style="width: 8.16%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">FOR</div>
              <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
              </div>
            </td>
            <td style="width: 9.88%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">AGAINST</div>
              <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
              </div>
            </td>
            <td style="width: 9.9%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">ABSTAIN</div>
              <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
              </div>
            </td>
            <td rowspan="2" style="width: 31.96%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0);">&#160;</td>
          </tr>
          <tr>
            <td style="width: 8.16%; vertical-align: top; text-align: center;">
              <div>&#9744;</div>
              <div> <br>
              </div>
            </td>
            <td style="width: 9.88%; vertical-align: top; text-align: center;">&#9744;</td>
            <td style="width: 9.9%; vertical-align: top; text-align: center;">&#9744;</td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 3.76%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 36.34%; vertical-align: middle; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25;">Do you have a &#8220;Personal Interest&#8221; (as defined in the Proxy Statement) with respect to the subject matter of Proposal 2?&#160; <font style="font-weight: bold;">(Please note: if you do not mark
                  either &#8220;YES&#8221; or &#8220;NO&#8221; your shares will not be voted on Proposal 2)</font></div>
              <div style="text-align: justify; line-height: 1.25;"><font style="font-weight: bold;"> <br>
                </font></div>
            </td>
            <td style="width: 8.16%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">YES</div>
              <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
              </div>
              <div style="text-align: center; line-height: 1.25; font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</div>
            </td>
            <td style="width: 9.88%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">NO</div>
              <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
              </div>
              <div style="text-align: center; line-height: 1.25; font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</div>
            </td>
            <td style="width: 9.9%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 31.96%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">&#160;</td>
          </tr>
          <tr>
            <td style="width: 3.76%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25;">3.</div>
            </td>
            <td style="width: 36.34%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25;">
                <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">TO APPROVE certain amendments to the Company&#8217;s Articles of Association relating to the appointment of directors of
                  the Company, including to classify the Board of Directors (other than the external directors) into three classes with staggered three-year terms, as set forth on Appendix A to the Proxy Statement.</div>
                <div style="line-height: 1.25">&#160;</div>
              </div>
            </td>
            <td style="width: 8.16%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">FOR</div>
              <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
              </div>
              <div style="text-align: center; line-height: 1.25; font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</div>
            </td>
            <td style="width: 9.88%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">AGAINST</div>
              <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
              </div>
              <div style="text-align: center; line-height: 1.25; font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</div>
            </td>
            <td style="width: 9.9%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">ABSTAIN<br>
                <br>
              </div>
              <div style="text-align: center; line-height: 1.25; font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</div>
            </td>
            <td style="width: 31.96%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          </tr>
          <tr>
            <td style="width: 3.76%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25;">4.</div>
            </td>
            <td style="width: 36.34%; vertical-align: middle; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25;">TO APPROVE the reappointment of Kesselman &amp; Kesselman, Certified Public Accountants (Isr.), a member firm of PricewaterhouseCoopers International Limited, as the Company&#8217;s independent
                registered public accounting firm for the year ending December 31, 2023 and for such additional period until the next annual general meeting, and to authorize the Audit Committee of the Board of Directors to fix the compensation of said
                auditors in accordance with the scope and nature of their services.</div>
              <div style="text-align: justify; line-height: 1.25;"> <br>
              </div>
            </td>
            <td style="width: 8.16%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">FOR</div>
              <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
              </div>
              <div style="text-align: center; line-height: 1.25; font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</div>
            </td>
            <td style="width: 9.88%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">AGAINST</div>
              <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
              </div>
              <div style="text-align: center; line-height: 1.25; font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</div>
            </td>
            <td style="width: 9.9%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">ABSTAIN</div>
              <div style="text-align: center; line-height: 1.25; font-weight: bold;"><br>
              </div>
              <div style="text-align: center; line-height: 1.25; font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</div>
            </td>
            <td style="width: 31.96%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          </tr>
          <tr>
            <td style="width: 3.76%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 36.34%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Name:</div>
              <div style="text-align: justify; line-height: 1.25; font-weight: bold;"> <br>
              </div>
              <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Number of shares:</div>
              <div style="text-align: justify; line-height: 1.25; font-weight: bold;"> <br>
              </div>
              <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Signature:<br>
                <br>
              </div>
              <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Date:</div>
              <div style="text-align: justify; line-height: 1.25; font-weight: bold;"> <br>
              </div>
              <div style="text-align: justify; line-height: 1.25;">NOTE: Please mark date and sign exactly as the name(s) appear on this proxy. If the signer is a corporation, please sign the full corporate name by a duly authorized officer. Executors,
                administrators, trustees, etc. should state their full title or capacity. Joint owners should each sign.</div>
              <div style="text-align: justify; line-height: 1.25;"> <br>
              </div>
            </td>
            <td style="width: 8.16%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 9.88%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 9.9%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 31.96%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25">
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>4
<FILENAME>exhibit_3.htm
<DESCRIPTION>PROXY CARD
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using Broadridge PROfile 23.5.1.5152
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <div style="line-height: 1.25; text-align: right;"><u><font style="font-weight: bold;">Exhibit 3</font></u><br>
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> <br>
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">BIOLINERX LTD.</div>
    <div style="line-height: 1.25; text-align: center;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Instructions to The Bank of New York Mellon, as Depositary </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">(Must be received prior to 12:00 p.m. EST on August 2, 2023)</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">The undersigned shareholder of BioLineRx Ltd. (the &#8220;Company&#8221;) hereby appoints Mali Ze&#8217;evi and/or Raziel Fried, and each or either of them, the true and
      lawful attorney, agent and proxy of the undersigned, with full power of substitution, to vote, as designated below, all of the ordinary shares of the Company which the undersigned is entitled in any capacity to vote at the Annual General Meeting of
      the shareholders of the Company which will be held at the offices of the Company at Modi&#8217;in Technology Park, 2 HaMa&#8217;ayan Street, Modi&#8217;in 7177871, Israel, on August 7, 2023 at 3:00 p.m. (Israel time), and all adjournments and postponements thereof.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">NOTES:</div>
    <div style="margin-left: 5.6pt; line-height: 1.25; font-weight: bold;"> <br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z76afba1512974cf88ecdad2c40ce962c" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 2.95pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 14.45pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">1.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Please direct the Depositary how it is to vote by placing an &#8220;X&#8221; in the appropriate box opposite each agenda item. It is
                understood that, if this form is signed and returned but no instructions are indicated in the boxes, then a discretionary proxy will be given to a person designated by the Company.</div>
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;"> <br>
              </div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z6d4402850405400182cd81473411e858" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 2.95pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 14.45pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">2.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">It is understood that, if this form is not signed and returned, the Depositary will deem such holder to have instructed the
                Depositary to give a discretionary proxy to a person designated by the Company.</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">(Continued and to be marked, dated and signed, on the other side)</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div> <br>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: 400;">
      <div style="text-align: center; margin-right: 66.7pt; margin-left: 55.05pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Annual General Meeting of Shareholders of </div>
      <div style="text-align: center; margin-right: 66.7pt; margin-left: 55.05pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;"> <br>
      </div>
      <div style="text-align: center; margin-right: 66.7pt; margin-left: 55.05pt; line-height: 1.25; font-size: 12pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">BIOLINERX LTD.</div>
      <div style="text-align: center; margin-right: 66.7pt; margin-left: 55.05pt; line-height: 1.25; font-size: 12pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> <br>
      </div>
      <div style="text-align: center; margin-right: 99.95pt; margin-left: 88.3pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">to be held on August 7, 2023 </div>
      <div style="text-align: center; margin-right: 99.95pt; margin-left: 88.3pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">For Holders as of June 30, 2023</div>
      <br>
      <div style="text-align: center; margin-right: 64.8pt; margin-left: 55.05pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;"><img width="23" height="21" src="image00001.jpg">&#160;<font style="font-weight: bold;"><u>MAIL</u></font></div>
      <div style="text-align: center; margin-right: 64.8pt; margin-left: 55.05pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;"><font style="font-weight: bold;"><u> <br>
          </u></font></div>
      <div style="text-align: center; margin-right: 64.8pt; margin-left: 55.05pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;"><font style="font-weight: bold;"><u> </u></font>
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" id="zcfa963782f444c9c9e9f14271911966e">

            <tr>
              <td style="width: 30%;">
                <div style="text-align: right;">&#8226;&#160;&#160;&#160;&#160; </div>
              </td>
              <td style="width: 70%;">
                <div>
                  <div style="text-align: left; line-height: 1.25;">Mark, sign and date your Voting Instruction Form.</div>
                </div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%;">
                <div style="text-align: right;">&#160;&#160;&#160;&#160;&#160; &#8226;&#160;&#160;&#160;&#160; <br>
                </div>
              </td>
              <td style="width: 70%;">
                <div>
                  <div style="text-align: left; line-height: 1.25;">Detach your Voting Instruction Form.</div>
                </div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%;">
                <div style="text-align: right;">&#160;&#8226;&#160; &#160;&#160; </div>
              </td>
              <td style="width: 70%;">
                <div>
                  <div style="text-align: left; line-height: 1.25;">Return your Voting Instruction Form in the postage-paid envelope provided.</div>
                </div>
              </td>
            </tr>

        </table>
      </div>
      <u> </u></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: 400;"><u> </u><br>
      <div style="text-align: center; margin-right: 6.45pt; margin-left: 9.55pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">All votes must be received prior to 12:00 p.m. EST on August 2, 2023.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; margin-right: 51.9pt; margin-left: 55.05pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">To view the notice and proxy statement, please visit:</div>
      <div style="text-align: center; margin-right: 51.9pt; margin-left: 55.05pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;"> <br>
      </div>
      <div style="line-height: 1.25;">
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" id="zb9cdbec8d2e245de806373e0d6126ce4">

            <tr>
              <td style="width: 45%;">
                <div>&#160;</div>
              </td>
              <td style="width: 55%;">
                <div>
                  <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">PROXY TABULATOR FOR </div>
                  <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(170, 170, 170); font-style: normal; font-variant: normal; text-transform: none;">BIOLINERX LTD.</div>
                  <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(170, 170, 170); font-style: normal; font-variant: normal; text-transform: none;">P.O. BOX 8016</div>
                  <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(170, 170, 170); font-style: normal; font-variant: normal; text-transform: none;">CARY, NC 27512-9903</div>
                </div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">
        <table cellspacing="0" cellpadding="0" border="0" style="width: 25%; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" id="z7b23366455f340b195101db2280bf74b">

            <tr>
              <td style="background-color: rgb(170, 170, 170); width: 100%; border-width: 1px; border-style: solid; border-color: rgb(0, 0, 0);">
                <div>&#160;</div>
                <div> <br>
                </div>
                <div> <br>
                </div>
                <div> <br>
                </div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25; font-weight: bold;">EVENT # </div>
      <div style="line-height: 1.25; font-weight: bold;"> <br>
      </div>
      <div style="line-height: 1.25; font-weight: bold;">CLIENT #</div>
      <div style="line-height: 1.25; font-weight: bold;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="line-height: 1.25;">
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 100%; vertical-align: top;">
                  <div style="text-align: center; margin-left: 1pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"> &#8595; Please separate carefully at the perforation and return just this portion in the envelope provided. &#8595;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
        </div>
      </div>
      <div style="line-height: 1.25;">
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div> <br>
        </div>
        <div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">Annual General Meeting of Shareholders of </div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
          </div>
          <div style="text-align: center; line-height: 1.25; font-size: 12pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">BIOLINERX LTD.</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="line-height: 1.25;"><font style="font-weight: bold;">Date:</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;August 7, 2023</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="margin-left: 45.75pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">See Voting Instruction On Reverse Side.</div>
          <div style="margin-left: 45.75pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;"> <br>
          </div>
          <div style="line-height: 1.25;"><font style="font-weight: bold;">Please make your marks like this:&#160;</font><font style="font-family: 'Segoe UI Symbol',sans-serif;">&#9746; </font><font style="font-weight: bold;">Use dark black pencil or pen only</font></div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="line-height: 1.25">
            <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" id="z022f3d1a666143219fc108d8e6b40248">

                <tr>
                  <td rowspan="1" style="width: 4%;">&#160;</td>
                  <td rowspan="1" style="width: 70%;">&#160;</td>
                  <td rowspan="1" style="width: 8%; text-align: center; font-weight: bold;">&#160;For </td>
                  <td rowspan="1" style="width: 8%; text-align: center; font-weight: bold;">&#160;Against </td>
                  <td rowspan="1" style="width: 8%; text-align: center; font-weight: bold;">&#160;Abstain</td>
                  <td rowspan="1" style="width: 1%;">&#160;</td>
                </tr>
                <tr>
                  <td style="width: 4%; text-align: left; vertical-align: top;">
                    <div>&#160;1.</div>
                  </td>
                  <td style="width: 70%;">
                    <div>
                      <div style="text-align: justify; line-height: 1.25;">TO APPROVE the re-election of the following persons to the Board of Directors, each to serve until the next annual general meeting of shareholders and until their respective
                        successors are duly elected and qualified, or each to serve for staggered terms ending at the 2024, 2025 and 2026 annual general meetings of shareholders, if Proposal 3 is approved:</div>
                      <div style="text-align: justify; line-height: 1.25;"> <br>
                      </div>
                    </div>
                  </td>
                  <td style="width: 8%;">
                    <div style="text-align: center;">&#160;</div>
                  </td>
                  <td style="width: 8%;">
                    <div style="text-align: center;">&#160;</div>
                  </td>
                  <td style="width: 8%;">
                    <div style="text-align: center;">&#160;</div>
                  </td>
                  <td style="width: 1%;">
                    <div>&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 4%;">
                    <div>&#160;</div>
                  </td>
                  <td style="width: 70%;">
                    <div>a.&#160;&#160;&#160; Aharon Schwartz</div>
                  </td>
                  <td style="width: 8%;">
                    <div style="text-align: center;">&#9744; <br>
                    </div>
                  </td>
                  <td style="width: 8%;">
                    <div style="text-align: center;">&#9744;</div>
                  </td>
                  <td style="width: 8%;">
                    <div style="text-align: center;">&#9744;</div>
                  </td>
                  <td style="width: 1%;">
                    <div>&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 4%;">
                    <div>&#160;</div>
                  </td>
                  <td style="width: 70%;">
                    <div>b.&#160;&#160;&#160; Michael Anghel</div>
                  </td>
                  <td style="width: 8%;">
                    <div style="text-align: center;">&#9744; <br>
                    </div>
                  </td>
                  <td style="width: 8%;">
                    <div style="text-align: center;">&#9744;<br>
                    </div>
                  </td>
                  <td style="width: 8%;">
                    <div style="text-align: center;">&#9744;</div>
                  </td>
                  <td style="width: 1%;">
                    <div>&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 4%;">
                    <div>&#160;</div>
                  </td>
                  <td style="width: 70%;">
                    <div>c.&#160;&#160;&#160;&#160; B.J. Bormann</div>
                  </td>
                  <td style="width: 8%;">
                    <div style="text-align: center;">&#9744;</div>
                  </td>
                  <td style="width: 8%;">
                    <div style="text-align: center;">&#9744;<br>
                    </div>
                  </td>
                  <td style="width: 8%;">
                    <div style="text-align: center;">&#9744;</div>
                  </td>
                  <td style="width: 1%;">
                    <div>&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 4%;">
                    <div>&#160;</div>
                  </td>
                  <td style="width: 70%;">
                    <div>d.&#160;&#160;&#160; Raphael Hofstein</div>
                  </td>
                  <td style="width: 8%;">
                    <div style="text-align: center;">&#9744;</div>
                  </td>
                  <td style="width: 8%;">
                    <div style="text-align: center;">&#9744;<br>
                    </div>
                  </td>
                  <td style="width: 8%;">
                    <div style="text-align: center;">&#9744;</div>
                  </td>
                  <td style="width: 1%;">
                    <div>&#160;</div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 4%;" rowspan="1">&#160;</td>
                  <td style="width: 70%;" rowspan="1">e.&#160;&#160;&#160;&#160; Sandra Panem </td>
                  <td style="width: 8%; text-align: center; font-weight: normal;" rowspan="1">&#9744;</td>
                  <td style="width: 8%; text-align: center; font-weight: normal;" rowspan="1">&#9744;</td>
                  <td style="width: 8%; text-align: center; font-weight: normal;" rowspan="1">&#9744;</td>
                  <td style="width: 1%;" rowspan="1">&#160;</td>
                </tr>
                <tr>
                  <td style="width: 4%; text-align: left; vertical-align: top;" rowspan="1">&#160;</td>
                  <td style="width: 70%;" rowspan="1">&#160;</td>
                  <td style="width: 8%; text-align: center; font-weight: bold;" rowspan="1">&#160;</td>
                  <td style="width: 8%; text-align: center; font-weight: bold;" rowspan="1">&#160;</td>
                  <td style="width: 8%; text-align: center; font-weight: bold;" rowspan="1">&#160;</td>
                  <td style="width: 1%;" rowspan="1">&#160;</td>
                </tr>
                <tr>
                  <td style="width: 4%; text-align: left; vertical-align: top;" rowspan="1">&#160;</td>
                  <td style="width: 70%;" rowspan="1">&#160;</td>
                  <td style="width: 8%; text-align: center; font-weight: bold;" rowspan="1">&#160;For&#160; </td>
                  <td style="width: 8%; text-align: center; font-weight: bold;" rowspan="1">&#160; Against </td>
                  <td style="width: 8%; text-align: center; font-weight: bold;" rowspan="1">&#160;Abstain <br>
                  </td>
                  <td style="width: 1%;" rowspan="1">&#160;</td>
                </tr>
                <tr>
                  <td style="width: 4%; text-align: left; vertical-align: top;" rowspan="1">&#160;2.</td>
                  <td style="width: 70%;" rowspan="1">
                    <div style="line-height: 1.25;">TO APPROVE the grant of equity compensation to Philip Serlin, the Company&#8217;s Chief Executive Officer, as described in Proposal 2 of the Proxy Statement.</div>
                    <div style="line-height: 1.25;"> <br>
                    </div>
                  </td>
                  <td style="width: 8%; text-align: center;" rowspan="1">&#9744; <br>
                  </td>
                  <td style="width: 8%; text-align: center;" rowspan="1">&#160;&#9744;</td>
                  <td style="width: 8%; text-align: center;" rowspan="1">&#9744; <br>
                  </td>
                  <td style="width: 1%;" rowspan="1">&#160;</td>
                </tr>
                <tr>
                  <td style="width: 4%; text-align: left; vertical-align: top;" rowspan="1">&#160;</td>
                  <td style="width: 70%;" rowspan="1">
                    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Do you have a &#8220;Personal Interest&#8221; (as defined in the Proxy Statement) with respect to the subject matter of Proposal 2? <font style="font-weight: bold;">(Please note: if you do not mark either &#8220;YES&#8221; or &#8220;NO&#8221; your shares will not be voted on Proposal 2)</font></div>
                  </td>
                  <td style="width: 8%; text-align: center; vertical-align: top;" rowspan="1">
                    <div style="margin-left: 2.45pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">Yes</font> <br>
                    </div>
                    <div style="margin-left: 2.45pt; line-height: 1.25;">&#9744;<font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;"> </font></div>
                  </td>
                  <td style="width: 8%; text-align: center; vertical-align: top;" rowspan="1">
                    <div>&#160;<font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">No</font></div>
                    <div>&#9744;<font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;"> </font></div>
                  </td>
                  <td style="width: 8%; text-align: center;" rowspan="1">&#160;</td>
                  <td style="width: 1%;" rowspan="1">&#160;</td>
                </tr>
                <tr>
                  <td style="width: 4%; text-align: left; vertical-align: top;" rowspan="1">&#160;</td>
                  <td style="width: 70%;" rowspan="1">&#160;</td>
                  <td style="width: 8%; text-align: center; vertical-align: top; font-weight: bold;" rowspan="1">&#160;</td>
                  <td style="width: 8%; text-align: center; vertical-align: top; font-weight: bold;" rowspan="1">&#160;</td>
                  <td style="width: 8%; text-align: center; font-weight: bold;" rowspan="1">&#160;</td>
                  <td style="width: 1%;" rowspan="1">&#160;</td>
                </tr>
                <tr>
                  <td style="width: 4%; text-align: left; vertical-align: top;" rowspan="1">&#160;</td>
                  <td style="width: 70%;" rowspan="1">&#160;</td>
                  <td style="width: 8%; text-align: center; vertical-align: top; font-weight: bold;" rowspan="1">&#160; For <br>
                  </td>
                  <td style="width: 8%; text-align: center; vertical-align: top; font-weight: bold;" rowspan="1">&#160;Against </td>
                  <td style="width: 8%; text-align: center; font-weight: bold;" rowspan="1">&#160;Abstain</td>
                  <td style="width: 1%;" rowspan="1">&#160;</td>
                </tr>
                <tr>
                  <td style="width: 4%; text-align: left; vertical-align: top;" rowspan="1">&#160;3.</td>
                  <td style="width: 70%;" rowspan="1">
                    <div style="text-align: justify; line-height: 1.25;">TO APPROVE certain amendments to the Company&#8217;s Articles of Association relating to the appointment of directors of the Company, including to classify the Board of Directors (other
                      than the external directors) into three classes with staggered three-year terms, as set forth on Appendix A to the Proxy Statement.</div>
                    <div style="text-align: justify; line-height: 1.25;"> <br>
                    </div>
                  </td>
                  <td style="width: 8%; text-align: center; vertical-align: middle;" rowspan="1">&#160;&#9744;</td>
                  <td style="width: 8%; text-align: center; vertical-align: middle;" rowspan="1">&#9744; <br>
                  </td>
                  <td style="width: 8%; text-align: center; vertical-align: middle;" rowspan="1">&#160;&#9744;</td>
                  <td style="width: 1%;" rowspan="1">&#160;</td>
                </tr>
                <tr>
                  <td style="width: 4%; text-align: left; vertical-align: top;" rowspan="1">&#160;4.</td>
                  <td style="width: 70%;" rowspan="1">
                    <div style="text-align: justify; line-height: 1.25;">TO APPROVE the reappointment of Kesselman &amp; Kesselman, Certified Public Accountants (Isr.), a member firm of PricewaterhouseCoopers International Limited, as the Company&#8217;s
                      independent registered public accounting firm for the year ending December 31, 2023 and for such additional period until the next annual general meeting, and to authorize the Audit Committee of the Board of Directors to fix the
                      compensation of said auditors in accordance with the scope and nature of their services.</div>
                  </td>
                  <td style="width: 8%; text-align: center; vertical-align: middle;" rowspan="1">&#9744; <br>
                  </td>
                  <td style="width: 8%; text-align: center; vertical-align: middle;" rowspan="1">&#160;&#9744;</td>
                  <td style="width: 8%; text-align: center; vertical-align: middle;" rowspan="1">&#160;&#9744;</td>
                  <td style="width: 1%;" rowspan="1">&#160;</td>
                </tr>

            </table>
          </div>
          <div style="line-height: 1.25"> <br>
          </div>
          <div style="line-height: 1.25">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">
                <div style="text-align: center; line-height: 1.25; font-weight: bold;">Authorized Signatures - This section must be completed for your instructions to be executed.</div>
              </div>
              <div style="line-height: 1.25">&#160;
                <table cellspacing="0" cellpadding="0" border="0" align="center" id="z0d3858951ccc4ef4ad3c7c6d2fe73258" style="width: 80%; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">

                    <tr>
                      <td style="border-top: 1px solid #000000; width: 30%;">
                        <div style="text-align: center;">&#160;Please Sign Here&#160;&#160; <br>
                        </div>
                      </td>
                      <td style="width: 40%;">
                        <div>&#160;</div>
                      </td>
                      <td style="border-top: 1px solid #000000; width: 20%;">
                        <div style="text-align: center;">Please Date Above</div>
                      </td>
                    </tr>
                    <tr>
                      <td style="width: 30%;">
                        <div style="text-align: center;">&#160;</div>
                        <div style="text-align: center;"> <br>
                        </div>
                      </td>
                      <td style="width: 40%;">
                        <div>&#160;</div>
                      </td>
                      <td style="width: 20%;">
                        <div>&#160;</div>
                      </td>
                    </tr>
                    <tr>
                      <td style="border-top: 1px solid #000000; width: 30%;">
                        <div style="text-align: center;">&#160;Please Sign Here&#160;&#160; <br>
                        </div>
                      </td>
                      <td style="width: 40%;">
                        <div>&#160;</div>
                      </td>
                      <td style="border-top: 1px solid #000000; width: 20%;">
                        <div style="text-align: center;">Please Date Above</div>
                      </td>
                    </tr>

                </table>
                <div> <br>
                </div>
              </div>
              <div style="text-align: justify; line-height: 1.25;">
                <div style="line-height: 1.25;">
                  <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
                <div style="line-height: 1.25">&#160;
                  <div style="text-align: left; margin-left: 479.65pt; line-height: 1.25;"><img width="22" height="24" src="image00004.jpg"></div>
                  <div style="text-align: left; margin-left: 38.4pt; line-height: 1.25;"><img width="148" height="1" src="image1.jpg">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: Arial, sans-serif; font-size: 1pt;"><img width="104" height="1" src="image2.jpg"></font></div>
                  <div style="text-align: left; margin-left: 70.75pt; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160; <br>
                  </div>
                  <div style="line-height: 1.25">&#160;</div>
                  <br>
                  <div style="line-height: 1.25">&#160;</div>
                  <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                  </div>
                </div>
                <br>
              </div>
            </div>
          </div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
        </div>
        <div> <br>
        </div>
        <br>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image00001.jpg
<TEXT>
begin 644 image00001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  J "\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#VS5-0NK:X
MM;33[>WN+N?>_ESSF)1&H&YLA6/!9!C'\5,.L7$!?[9H]]$B#)EA59U/^Z$)
M<_\ ? J-+B$Z[J=]//%';:?"EN7D(41,1YLA+'C!5H?^^:IQ_$/PA->+:1Z_
M9M,QVJ YP3Z!L8/YT :D&OZ3<3I;K?PI<N,K;S'RI<?[C8;]*R->UZ196L[-
M]NWB213SGT'I7,?$;XHZ)IVASZ?I5U;:CJ-PA1?+(ECA!XW,>02.PYYZ\5Y#
M8_%'Q7:"-)K]+^)!Q'>PK+GZL1N_6@+'L:7,\<OFI-(LAZL&.379:!K#:C$T
M4Y'VB,9)'\0]:\TTC6-?U/1+#4YO!R74%Z[;9=*N\%54$DE&W =",%AR,<$@
M'<\(:]INJ0KK.FM=QVZSM;/%=1JK$[-QY5CD#*^G6F!F_$*Y\_X9ZI:>:\>H
MR71N9K6:,QRO'YV>%(^=44H-RY&%ZUY3X(@M[MYXGT^TN+J-T>W;^TS970?/
M'DL3L)&,X(SG%?5SQK(N&&<<@]P?4>]>6^)?">B7]Y-#K&DQ&<Y(O+0>1*P/
M\1P-K'_>!I#N<KJ4JRSBTU:XA:5AY:6WBW3S#+M'4I>1=?J2!7"^,=%73)K6
MX@T6;3;>Y4E2+U;N"3'>.11TQV))YKT!O"?B/2K=H?#/B&/4+ C!TK5%7!&>
M%"OF,Y]05->7>([#4['5YCJ>DG2Y)7+"!83'&/78#U7Z$B@#WG_A,_#>G?#"
M[LM#U6VGN+&P2+:C?8W9G7!9>/O_ 'FPN?FX)!.:CT'29-+T'2-'PPN(X/-G
MW#YO.D^=@?7&0O\ P&O%O NC)KGC+3K290;99//N,KD>4@W,#]0,?B*^B=!5
M[_Q URXZ;Y&].>,?K^E-"9VE4-4TN'4[?8_RR+]QP.G_ -:K]%(#SJ]TVZT]
M]L\1"YX<<J?QJ'[0SVS6LZQW-JWWK>X021G_ ("V17I1 8$$ @]0:Y#Q#;P0
MS 10QQC_ &% IB.9TS1-$TN[NKK2=+:UOKN+R&$4K-'M+!CM4Y()P!@'&/2O
C0=!TLZ;9DR@>?+R_MZ"C0H(4LED6&-9#P6"@$_C6K0,__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image1.jpg
<TEXT>
begin 644 image1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" .> ' # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image2.jpg
<TEXT>
begin 644 image2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" .> )\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
6*** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image00004.jpg
<TEXT>
begin 644 image00004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,? NH# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
